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ABSTRACT OF THE DISSERTATION 
 
Generation and Utilization of Diverse Memory B Cells After Flavivirus Challenges 
by 
Rachel Wong 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2020 
Professor Deepta Bhattacharya, Chair 
Professor Paul Allen, Co-Chair 
Over the course of an effective immune response to an infection, two distinct B cell 
populations are generated to provide protection against reinfection, long-lived plasma cells 
(LLPCs) and memory B cells (MBCs).  LLPCs and MBCs originate from germinal center (GC) 
B cells that have undergone B cell receptor (BCR) affinity maturation through iterative rounds of 
somatic hypermutation, proliferation, and selection.  Thus, LLPCs and MBCs can bind to their 
antigen with higher affinity than their naïve B cell precursors.  LLPCs constitutively secrete 
antibodies and can provide sterilizing immunity that pre-exists subsequent infections.  MBCs, on 
the other hand, are quiescent and provide protection only after being re-activated.  Re-activation 
of MBCs can result either in the re-initiation of GC reactions to mold and affinity mature BCRs 
toward new specificities or in the differentiation into plasma cells.  However, the likelihood of 
re-activating MBCs in the presence of pre-existing serum antibodies secreted by LLPCs is low.  
Thus, the etiological role of MBCs is not well defined.  We previously showed that MBCs are 




antibodies secreted from LLPCs, though it is unclear the breadth of diverse antigens recognized 
by MBCs.   
Here, we demonstrate that the diversity of MBCs extends to recognizing heterologous 
antigens.  Using mouse models of sequential heterologous flavivirus vaccinations and activation 
induced cytidine deaminase conditional knockout mice in which affinity maturation is ablated, 
we observed that MBCs respond to heterologous antigens without further affinity maturation and 
remodeling of their BCRs.  Instead, MBCs respond by directly differentiating into plasma cells 
to secrete antibodies, some of which are neutralizing, targeting the secondary pathogen.  Thus, 
the diversity of MBCs generated after a primary response dictates the response to subsequent 
heterologous challenges.  Mechanistically, this diversity results from the continued, active 
recruitment of low affinity germinal center B cells into the MBC pool.   
Given the different roles of LLPCs and MBCs upon secondary challenge by either a 
homologous or heterologous pathogen, understanding the durability of LLPC and MBC recall 
responses can provide insights on how to modulate length of responses.  We previously showed 
that two members of the Broad complex, tramtrack, bric-a-brac-poxvirus, and zinc finger (BTB-
POZ) family of transcription factors, ZBTB20 and ZBTB32, regulate distinct aspects of B cell 
memory responses.  ZBTB20 regulates adjuvant-dependent survival of long-lived plasma cells, 
while ZBTB32 regulates the durability of recall response.  Although the mechanisms of how 
ZBTB20 and ZBTB32 regulate responses is unclear, the N-terminal BTB-POZ domain likely 
recruits transcriptional repressors to different areas of DNA binding mediated by the C-terminal 
zinc finger domains.  Thus, we hypothesized that ZBTB38, another member of the BTB-POZ 




hematopoietic cells, we demonstrate that ZBTB38 is dispensable for both primary and recall 
responses to a hapten immunogen.   
Taken together, we propose that the MBC diversity after a primary response is generated 
by the continued, but active, selection of low affinity germinal center B cells into the MBC pool, 
and that this diversity is directly utilized upon secondary challenges without further affinity 
maturation.  In addition, both the primary B cell and MBC recall responses do not require 
expression of ZBTB38.  Further work needs to be done defining the recall responses of MBCs to 
live viruses and cues that promote the continuous selection of low-affinity GC B cells into the 



















The contents of this chapter have been previously published in Immunology. Personal 
contributions include writing and editing this review in collaboration with Deepta Bhattacharya.   
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Protective immunity elicited by almost all vaccines and many infections is mediated by 
pathogen-specific B cells and antibodies. The generation of such protective cells and antibodies 
is mediated by a process of clonal expansion and diversification of fates, followed by a 
contraction to the essential components of durable immunity. For T cell-dependent responses, 
naïve B lymphocytes that recognize cognate antigens rapidly proliferate and differentiate into 
short-lived plasma cells or germinal center B cells 1.  Short-lived plasma cells secrete low-
affinity antibodies that are important for the initial defense against pathogens such as West Nile 
virus 2, 3, and are thought to live for only several days 4.  Germinal center B cells progressively 
affinity mature their B cell receptors through multiple rounds of somatic hypermutation and 
selection 5, 6, 7.  Cells carrying affinity-enhancing mutations can then differentiate into memory B 
cells or long-lived plasma cells 8, 9.   
Long-lived plasma cells constitutively secrete affinity-matured antibodies that pre-exist 
subsequent infections, thereby providing sterilizing immunity 10, 11. These long-lived plasma cells 
can live up to an entire human lifetime in the absence of cellular division 12. Yet their persistence 
varies greatly with the specific infection or vaccine for reasons that still remain unclear. 
Metabolic, but not transcriptional pathways appear to be the major determinants of plasma cell 
longevity 13, 14, but how infection- or vaccine-specific properties such as antigen avidity, innate 
immune activation, and T cell help influence these programs remain unknown. Pathogens that 
evade pre-existing serum antibodies may be recognized by memory B cells, which make up a 
second line of defense 15, 16.  Memory B cells are quiescent, do not require continued antigenic 
stimulation for survival, and are more easily reactivated than are their naïve counterparts 17, 18.  




19, 20 and thus the focus of this article will be on memory B cells during recall responses in the 
context of real-world infections.   
During a recall response, reactivated memory B cells can differentiate into antibody-
secreting cells and/or germinal center B cells, depending on the responding subpopulation.  In 
mice, memory B cell subpopulations were initially distinguished by immunoglobulin isotype 
expression 21, 22. These studies showed that IgG+ memory B cells preferentially generate plasma 
cells, whereas IgM+ cells re-initiate germinal center reactions. Subsequent studies reported that 
CD80 and PD-L2 expression on antigen-specific cells are functional markers that distinguish 
memory subsets irrespective of isotype 23.  CD80+PD-L2+ cells are poised to differentiate into 
antibody-secreting cells, CD80-PD-L2- cells robustly differentiate into germinal center B cells, 
and CD80-PD-L2+ cells possess an intermediate ability to differentiate into antibody secreting 
cells and re-initiate germinal center reactions.  These markers mostly, but not fully correlate with 
IgM (enriched in the CD80-PD-L2-) or IgG (enriched in the CD80+PD-L2+) usage. Moreover, the 
specific isotype used by memory B cells correlates with unique transcriptional programs that 
support function and development 24. It is likely that the isotype is a marker of the innate signals 
received by memory B cells during ontogeny rather than a causative determinant of a specific 
transcriptional program 25. In humans, memory B cells are identified based on CD27 26, 27 
expression , and as in mice, their fate upon reactivation can be predicted by surface Ig 
expression.  Similar to mouse memory B cell subpopulations, IgG+ human memory B cells are 
poised to differentiate into antibody secreting cells, and IgM+ memory B cells are predisposed to 
form germinal center-like cells ex vivo 28. This correlation is reassuring, as mouse models allow 
for a deeper mechanistic understanding of cellular behavior, whereas studies in humans bring a 




has been identified in tonsils 29.  These cells express neither CD27 nor CD21, and express high 
levels of inhibitory receptor FcRL4 or FcRL5 29, 30.  These cells tend to be hyporesponsive to 
BCR stimulation, and are expanded in the blood in chronic infections like malaria and HIV 31, 32.  
Understanding the recall behavior of each memory B cell subpopulation in different infections is 
important for determining how to establish protective immunity, particularly when faced with the 
challenge of vaccinating a population that is already partially immune to an endemic pathogen.   
Here, we focus on flavivirus and Plasmodium infections as they pose some unique 
challenges for generating immunity.  As a result, there are interesting lessons to be applied to the 
basic study of memory B cells. Reciprocally, principles from the cell biology of memory B cells 
can be potentially applied to vaccination efforts. As examples of the challenges that these 
globally relevant pathogens pose, infections of flavivirus-immune individuals by heterologous or 
heterotypic strains can result in markedly exacerbated symptoms compared to the primary 
challenge.  Malaria, caused by Plasmodium infections, is characterized by the lack of a durable 
antibody response, and requires multiple exposures to develop naturally acquired immunity.  For 
each infection, we will discuss the underlying antibody and memory B cell responses, speculate 
on the ideal memory B cell response that considers the challenges faced, and conclude on 
implications for vaccine design and remaining questions.  We fully acknowledge that many 
aspects of this review are speculative. Yet we believe it is imperative to apply the fundamentals 
of memory B cell biology to contemporary, problematic infections to better guide vaccine design 
and future research.   
1.1 Flavivirus pathogenesis, epidemiology, and immunity  
Flaviviruses present a global threat to public health, especially with the recent emergence 




include the human pathogens ZIKV, West Nile Virus (WNV), Dengue virus (DENV), and 
Japanese Encephalitis virus (JEV).  These viruses are mainly transmitted by mosquitoes, and for 
WNV and JEV, humans are a dead-end host. For the epidemic pathogens YFV, DENV, and 
ZIKV, viral titers in humans can reach sufficient levels that these pathogens can be re-
transmitted by mosquitoes or by direct human-human contact 33, 34.  Most infections are 
asymptomatic or present mild symptoms, such as fever, arthralgia, and myalgia.  However, some 
cases of severe symptoms, such as severe hemorrhagic fever and vascular leakage, have been 
reported.  These severe symptoms have been largely associated with secondary DENV 
infections.   
DENV has four serotypes, DENV1 to DENV4, all of which co-circulate in the same 
geographic regions.  Work by Sabin in the 1950s showed that DENV infection by one serotype 
provided lifelong protection against homotypic infection, but not against heterotypic infections 
35.  Indeed, heterotypic infections increase the severity of symptoms when infections occur after 
antibodies generated from the primary challenge waned 36.   Thus, primary DENV infection 
generates a durable, serotype-specific antibody response that can be harmful to the host upon 
heterotypic challenge.  The increased severity of secondary infections is thought to be mediated 
by antibody-dependent enhancement (ADE), a process whereby antibodies that neutralize poorly, 
either due to epitope specificity or insufficient concentrations, enhance viral uptake via Fc 
gamma receptors on mononuclear phagocytes 37, 38, 39.  In addition to the humoral contribution 
(ADE) to increased disease severity upon heterologous infection, there is also a cellular 
contribution termed original antigen sin (OAS).   
The OAS hypothesis was first described as “the imprint established by the original virus 




infection are activated during subsequent infections.  When antigenic determinants vary between 
strains, these memory B cells can often bind only weakly and provide poor protection to the 
second infection. Yet by virtue of reduced activation requirements, these ineffective recall 
responses dominate over primary naïve B cells. For DENV, OAS was first described after 
observations that while serum antibodies had varying degrees of neutralizing activity to all four 
DENV serotypes after heterotypic DENV infection, potent neutralization only occurred to the 
primary infecting serotype 41.  Similar observations have since been made for memory T cells 42. 
Given the overlap in the geographical prevalence of many flaviviruses, increases in travel, and a 
potentially exacerbated immune response to secondary infections, there is a need for 
understanding recall responses to heterologous flavivirus infections.  To understand why non-
protective antibodies dominate secondary responses, we must first discuss the different antibody 
epitopes in flavivirus infections.   
1.1.a Non-protective and protective antibodies in response to flavivirus infections 
Most flavivirus antibodies target epitopes found on the envelope (E) protein, which 
mediates cellular attachment and membrane fusion to the host cell 43.  The E protein contains 
three different domains (DI to DIII) with both non-protective and protective epitopes 44. The 
primary, non-protective epitope on the E protein is the DII fusion loop (DII-FL), which is highly-
conserved across flavivirus species 45, 46, 47.  In humans, this is the immunodominant epitope 46, 
and explains why antibodies from one flavivirus infection can cross-react with other flaviviruses 
that have yet to be encountered 48. In addition, these DII-FL antibodies are frequently poorly-
neutralizing.  For many other types of infections, the presence of such non-neutralizing 
antibodies is at worst harmless, and at best protective due to engagement of alternate antibody 




antibodies pathogenic in acute secondary flavivirus infections 37.  How these non-protective 
epitopes impact the cellular response in secondary infections is discussed next.   
As mentioned above, in humans, antibodies generated during primary infections are 
mostly directed against DII-FL, and have poor neutralization ability 46.   During acute secondary 
infections with a different DENV serotype, plasmablasts secrete cross-reactive, E-specific 
antibodies with varying degrees of ADE 49, 50.  These antibodies carry high levels of mutations, 
suggesting that they originate from memory B cells.  Memory B cells established after primary 
and secondary infections appear to retain a greater breadth of antigen specificities (E, prM, and 
complex epitopes) than do the responding plasmablasts (predominately E) 51, 52.   Thus, only a 
subset of memory B cells differentiates into antibody secreting cells, where the majority of 
antibodies are poorly neutralizing with high ADE activity. Similar findings were observed 
following ZIKV infection of DENV-immune patients 53, 54, 55, 56, 57. Vaccines to protect against 
flavivirus infections have thus far revealed similar problems.  A licensed tetravalent Dengue 
vaccine, CYD-TDV, can mount a neutralizing response to all four DENV serotypes 58.  
However, a longitudinal study on the efficacy of CYD-TDV found an increased risk of severe 
disease in previously unexposed individuals compared to those who had previously been exposed 
to at least one DENV serotype through natural infection 59.  Thus, CDY-TDV likely promotes 
ADE upon natural secondary DENV infection, at least in a subset of individuals who were naive 
prior to vaccination.  These findings demonstrate the importance of engaging B cells with 
strongly neutralizing specificities while avoiding those that preferentially enhance infection.     
While non-protective epitopes dominate the human antibody response, mouse studies 
have provided critical insight on protective epitopes that can potentially be targeted selectively.  




flavivirus infections 2. Passive transfer of minute quantities of immune serum from WNV-
convalescent mice into B-cell deficient animals confers protection to homologous virus infection 
2.  Analysis of mouse monoclonal antibodies has revealed that the most potent neutralizing 
epitopes are located on the lateral ridge epitope of DIII (DIII-LR) 45, 60, 61, 62, 63.  Interestingly, 
these DIII-LR specific antibodies are immunodominant in mice, whereas in humans these 
specificities clearly exist but are overwhelmed by DII-FL-reactive cells and antibodies 38, 45, 46, 64.  
The DIII-LR epitope is only weakly conserved across flavivirus species, and thus, long-lived 
plasma cell DIII-LR responses provide type-specific immunity with minimal ability to promote 
ADE 61, 63. Another protective and highly neutralizing epitope is the recently described E dimer 
epitope (EDE), present in both DENV and ZIKV 65, 66.  Analysis of anti-EDE antibodies isolated 
from DENV-infected humans found that these antibodies potently and broadly neutralized all 
four DENV serotypes and ZIKV 53, 65, 66.  This epitope is present on intact, mature virions but not 
on recombinant E, indicating that a quaternary structure is required for antibody recognition. 
Because of the complexity of this epitope, an equally complex strategy will likely be required to 
selectively generate EDE-specific antibody responses. 
1.1.1b Diversity of memory B cells and their reactivation in secondary challenges 
Interestingly, mouse studies on WNV infections and vaccinations have demonstrated a 
greater diversity of DIII antigenic specificities in memory B cells than in long-lived plasma cells 
16. This fundamental difference in repertoires between memory B cells and constituent serum 
antibodies has also been found in humans following a range of different vaccines 15. The 
diversity of WNV-reactive memory B cells imparts them with the ability to cross-react to JEV 
DIII upon secondary challenges 16. These data suggest an ability of DIII-specific memory B 




upon secondary exposures. This could lead to potent cross-neutralizing responses if these 
memory B cells were to be selectively engaged. Several innovative potential solutions are 
possible.  For example, Richner et al. used a modified RNA to  express replication-incompetent 
ZIKV subviral particles carrying a mutation in the non-neutralizing DII-FL epitope 67.   Mice 
challenged with this modified RNA were resistant to subsequent DENV2 challenge, whereas 
animals immunized with wild-type ZIKV subviral particles w-ere highly susceptible to 
heterologous infections.  A second potential approach involves the use of DIII subunit vaccines. 
Multivalent or sequential DIII-based vaccines could potentially be given to specifically elicit 
DIII-LR neutralizing antibodies, either from naïve B cells or pre-existing memory B cells in 
subjects that are already immune to at least one flavivirus strain. In seropositive individuals, 
responses to heterologous DIII-LR epitopes would require clonal expansion and plasma cell 
differentiation of pre-existing cross-reactive DIII-LR-specific IgG+ memory B cells (Figure 1). 
Alternatively, engagement of IgM+ memory B cells specific for DIII-LR of one strain could re-
initiate germinal centers to affinity mature towards DIII-LR of the new strain (Figure 1).  A real-
life example where cross-reactive DIII-LR-specific antibodies were expanded in secondary 
infections involved ZIKV infection in DENV1-experienced individuals 56.  DENV1 and ZIKV 
share two critical amino acids in DIII, and thus memory B cells recognizing this epitope were 
selectively expanded.  Tapping the potential of pre-existing DIII-LR memory B cells may guide 
the best vaccination strategy to elicit potently neutralizing antibodies. Yet different 
considerations will need to be employed for vaccines that fail not because of their epitope 






1.2 Durability of plasma cell survival and antibody responses--the Achilles heel of malaria 
vaccines 
Malaria is caused by the Plasmodium parasite, and the P. falciparum species is the 
leading cause of death and disease in many developing countries, particularly in Africa 68.  Over 
half of the world’s population is at risk for malaria, where over 200 million cases of clinical 
malaria occur each year 68.  In addition, over 400,000 deaths, primarily in children, occur each 
year 68.  Protection against re-infection depends on the presence of long-lasting, neutralizing 
serum antibodies 69 as  passive transfer of immune serum into actively infected individuals 
results in rapid recovery 70.  However, Plasmodium infections themselves do not reliably 
generate durable antibody responses 71; not only are antibodies inefficiently generated, they are 
lost in the absence of consistent repeated exposure 72.  Given the high infection and mortality 
rate, especially in sub-Saharan African children, development of a highly effective vaccine is of 
utmost importance, but the provision of durable immunity poses a major challenge as described 
more below.   
The most advanced approach is the RTS,S subunit vaccine containing the 
circumsporozoite protein (CSP).  Preliminary studies revealed that vaccination in malaria-naive 
adults yielded robust antibody responses in which 86% were protected from subsequent 
Plasmodium challenge 73.  Though CSP-specific antibody titers gradually waned, these initial 
findings showed promise for a realistic and scalable vaccine against malaria.  However, a study 
analyzing vaccine efficacy in the field found that only 34% of Plasmodium partially-immune 
Gambian adults given the vaccine were protected from the first round of natural infection 74.  
Within 6 months post-RTS,S vaccination, both antibody titers and epidemiological protection 




side comparison, these data suggest that the ability of Plasmodium-naive individuals to mount 
and maintain a protective response after vaccination is higher than that of Plasmodium-
experienced individuals.  These findings further suggest that natural Plasmodium exposures may 
alter the ability of B cells to respond, either directly or indirectly. Alternatively, a response 
against CSP may intrinsically be short-lived (discussed below).  Several elegant studies have 
followed the B cell response over time in malaria-endemic areas, and have provided intriguing 
clues as to the source of the dysfunction. 
1.2.a Atypical memory B cells in Plasmodium infected individuals 
Repeated exposures to Plasmodium over the course of multiple wet seasons lead to a 
progressive increase in antibodies, but this protective humoral immunity rapidly fades during dry 
seasons as the mosquito population diminishes 77. There is also a progressive increase in the 
frequency of atypical memory B cells, balanced by a relative decrease in classical memory B 
cells 32, 78, 79.  These atypical memory B cells might be the key to understanding why antibody 
responses are so transient following vaccination or repeated natural infections 32. Originally 
identified in HIV patients by expression of the inhibitory receptor FcRH4, these cells fail to 
proliferate in response to BCR ligation 29, 80. Moreover, studies of the mouse age-related memory 
B cells, the potential analog to human atypical memory B cells, have shown markedly elevated 
expression of the transcription factor Zbtb32 81. This factor suppresses the duration of plasma 
cell survival following memory B cell recall responses 82. Thus, it might be that recall responses 
mounted by atypical memory B cells are inherently transient.  
There remain some conflicting findings regarding the biological properties of atypical 
memory B cells. For example, analysis of a relatively small number of cells suggested that 




individuals83 whereas another larger study found these two cell types to possess overlapping 
immunoglobulin repertoires 80. Some studies observed Ig secretion by atypical memory B cells 
both in vivo and ex vivo 83, while others have found these cells to be completely unresponsive to 
stimuli 80. A recent study by Pérez-Mazliah et al. analyzed the MSP1-specific memory B cell 
compartment following Plasmodium infection and found that atypical memory B cells were 
short-lived and had activated B cell and plasmablast gene signatures 84.  Mouse studies have not 
resolved these issues, as age-associated memory B cells can readily respond to Toll-like receptor 
stimulation 85, 86, whereas in some studies, human atypical memory B cells do not 87.  Clearly, 
additional studies must be performed to explain the differences in these sets of studies. This in 
turn will help define whether these cells should be intentionally avoided in vaccine strategies, or 
whether they can be safely ignored. 
A second finding that may impact the transience of immunity is the emergence of an 
unusual T follicular helper (Tfh) cell phenotype. Mouse studies have shown that a pro-
inflammatory environment promotes T-bet expression in pre-Tfh cells, which skews toward a 
Th1-like phenotype 79.  Similarly, human circulating Tfh-like cells from Plasmodium-immune 
individuals are poised to secrete interferon gamma (IFN- ) and  promote T-bet expression in 
atypical memory B cells 79, 88.  The high levels of T-bet expression in atypical memory B cells 
are associated with decreased BCR signaling and a switch from IgG1 to IgG3 surface expression 
88. In some cases, T-bet expression limits the ability of B cells to differentiate into germinal 
center B cells, and ultimately results in reduced IgG antibody titers 89, though in other cases it 
appears that Tbet expression actually enhances serum IgG2c levels 24, 90. Thus, severe malaria is 
associated with an inflammatory environment that results in a defective adaptive immune 




gradual acquisition of T-bet that is eventually enriched in the atypical memory B cell 
compartment 79, 88.  Thus, T-bet expression may result in impaired recall responses through its 
effects on atypical memory B cells.   
1.2.b Alternatives in mounting a durable anti-Plasmodium antibody response 
Based on the evidence provided above, there are several aspects to consider to develop a 
successful vaccine that provides durable immunity to malaria. First, the outcome of the immune 
response changes greatly with exposures. Thus, developing vaccines by testing on naive Western 
populations may not be fully predictive of the response in malaria-endemic areas 87, 91. Along 
these lines, it may become necessary to either productively engage atypical memory B cells to 
'awaken' them to produce long-lived plasma cells, or to avoid them entirely and target the 
classical memory populations instead (Figure 2). This latter strategy would depend on the 
existence of at least some non-overlapping antigen specificities between atypical and classical 
memory B cells. How best to awaken atypical memory B cells is far from clear, but engagement 
of certain pattern- or danger-associate molecular patterns might still be possible. Our own work 
has demonstrated that Zbtb32, which is highly expressed by age-associate memory B cells, 
restrains the duration of antibody production after recall responses to some challenges, such as 
murine cytomegalovirus and alum-adjuvanted immunogens 92.  In contrast, Zbtb32 has no role in 
controlling recall responses to intestinal bacteria, influenza booster vaccinations, or Ribi-
adjuvanted immunogens 92.  Thus, selection of proper adjuvants and innate stimuli can greatly 
influence the survival program engaged by plasma cells and the duration of immunity 93, 94.  
A second, and potentially more problematic scenario, is that inherent constraints within 
the human germline repertoire or pathogen evasion mechanisms prevent durable responses to 




malaria-naïve individuals than in malaria-experienced subjects, antibody responses still faded 
quite rapidly relative to a number of more robust vaccines and infections 95, 96. To define the 
underlying cause to these problems, a recent mouse study demonstrated that blood-stage 
parasites actively suppress the response to CSP 97. Other animal studies using different 
immunization and infection models have demonstrated that both the avidity of the antigen for its 
target BCR as well as the self-reactivity of the starting naïve B cell can greatly influence the 
duration of immunity. Studies using the model antigens demonstrated that when the starting 
avidity of the antigen is very high, paradoxically the duration of IgG memory B cell persistence 
is diminished 98. Additionally, high model antigen avidity promotes the expansion of short-lived 
plasma cells 99, 100. Yet in the context of HIV infection, a minimum antigen affinity is essential to 
effectively recruit pathogen-specific B cells into the response 101. Thus, it may be that an antigen 
avidity 'sweet spot' is required to generate the ideal durable response to Plasmodium. Adding to 
this complication is that some foreign antigen-specific B cells are also somewhat self-reactive, 
thereby diminishing their contribution to or durability following the response 102, 103, 104, 105. These 
problems can begin to be addressed by empirical antigen redesign and experimental animal 
studies. For example, although blood stage infection inhibits responses to CSP, responses to 
merozoite surface protein 1 remain intact and protect mice from subsequent infection 97, 106. 
Targeting naive B cells of very rare specificities may be an alternate but effective 
strategy. For instance, while antibody responses to the four amino acid (NANP) repeats of CSP 
increase over time post-infection, this is not due to increases in affinity maturation within the 
germinal center.  Instead, recruitment of naïve B cells with higher affinity than responding 
memory B cells drives these increases, as somatic hypermutations are often not affinity-




antibodies that recognize multiple P. falciparum isolates 108.  These highly unusual antibodies 
have inserted the collagen binding domain of LAIR1, an Ig superfamily inhibitory receptor, 
between the V and DJ segments.  Somatic mutations in the LAIR1 domain abolished binding to 
collagen and increased binding and opsonization of infected erythrocytes. These broadly reactive 
antibodies were isolated from IgG+ Memory B cells, and found to be highly clonally expanded 
in the two donors studied.  Thus, targeting high affinity naïve B cells may be a way to avoid 
atypical memory B cells and produce durable immunity.   
There are still many outstanding questions on the association and causation between 
malaria severity and atypical memory B cells.  Longitudinal studies analyzing the repertoire of, 
and clonality between, the memory B cell and plasmablast compartments after each malaria 
season will be important for understanding the development and contribution of atypical memory 
B cells.  Are atypical memory B cells originally classical memory B cells that have been 
exhausted or are they a separate fate during germinal center reactions?  Given that naturally 
acquired immunity is associated with an expanded atypical memory B cell pool, what is the 
association between protection and atypical memory B cells?  In addition, there appears to be 
different subsets of atypical memory B cells based on T-bet expression and/or isotype 
expression.  Do the functions of these different subsets differ in recall response?  In this case, 
malaria is a good infection system to use to study different aspects of atypical memory B cell 
biology.   
1.3 Conclusion 
Decades of research in model organisms have defined the basic and essential elements of 
cellular and humoral immunity. Increasingly sophisticated analysis in the field has revealed 




of mouse models that accurately mimic these issues 109. Of course not all aspects of responses are 
identical between humans and mice, but our viewpoint is that evolution likely preserves the most 
fundamental aspects of antibody responses. Even in the cases where there are differences 
between mice and humans, such as in the immunodominant antigens after flavivirus infection, 
mouse studies have revealed critical neutralizing epitopes that may form the basis for new human 
vaccines. As increasing numbers of reports define new structure-based methods to elicit epitope-
specific antibodies, basic studies will help guide these specificities into the correct cellular 
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Figure 1.1 Actual and ideal responses to heterologous flavivirus infections.  
Secondary flavivirus infections in humans can result in pathogenic responses, where the 
immunodominant epitope is the highly conserved fusion loop on the envelope protein domain II 
(DII-FL). Non-neutralizing DII-FL antibodies facilitate increased viral load through a process 
called antibody-dependent enhancement (ADE). Ideally, the response to heterologous challenge 
should result in the expansion of protective antibodies and memory B cells. This can either be 
achieved by recruiting DIII-LR cross-reactive IgM+CD80-PD-L2- memory B cells into the 
germinal center (GC) response to affinity mature towards the new heterologous DIII-LR epitope, 
or by differentiating pre-existing cross-reactive DIII-LR specific IgM+CD80+PD-L2+ memory B 






Figure 1.2 Actual and ideal response to Plasmodium.  
Plasmodium infections in humans result in expanded, hyporesponsive atypical memory B cells 
(aMBCs), contracted classical memory B cells (cMBCs), and short-lived antibody responses. 
Each additional infection by Plasmodium results in further increases in aMBCs and short-lived 
plasma cells (SLPCs). Therefore, multiple infections are needed for immunity. Given this 
challenge, vaccines need to be carefully designed to induce long-lived plasma cells (LLPCs) for 
a robust and durable response. To mount a robust and durable response, either adjuvants that can 
render aMBCs responsive must be used, or memory B cells that can recognize epitopes that 
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Memory B cells (MBCs) can respond to heterologous antigens either by molding new 
specificities through secondary germinal centers (GCs) or by selecting pre-existing clones 
without further affinity maturation. To distinguish these mechanisms in flavivirus infections and 
immunizations, we studied recall responses to lateral ridge epitopes, which are potently 
neutralizing but poorly conserved across species. Conditional deletion of activation induced 
cytidine deaminase (AID) between heterologous challenges of West Nile, Japanese encephalitis, 
Zika, and Dengue viruses did not affect the quality and quantity of recall responses. DIII-LR-
specific MBCs were contained mostly within the plasma cell-biased CD80+ subset and few GCs 
arose following heterologous booster vaccinations, demonstrating that recall responses are 
confined by pre-existing clonal diversity. Measurement of monoclonal antibody binding affinity 
to DIII proteins, timed AID deletion, single cell RNA-sequencing, and lineage tracing 
experiments suggest continuous commitment of relatively low affinity MBCs in the first weeks 
of the GC as a mechanism to promote diversity. Restricting this diversity through immunogen 
design may allow for generation of type-specific vaccines with little potential for infection 





After clearance of infections or vaccines, long-lived plasma cells (LLPCs) and memory B 
cells (MBCs) persist to maintain durable humoral immunity. While MBCs proliferate and 
differentiate into effector lineages upon antigen re-exposure, LLPCs constitutively secrete 
antibodies irrespective of the presence of antigen and can provide sterilizing immunity against 
subsequent homologous or closely related infections 1, 2. Because of these properties, LLPC-
derived circulating antibodies can also sequester antigen that would otherwise activate MBCs 3, 4. 
From an evolutionary standpoint, it seems unlikely that MBCs serve solely as an adjunct to 
LLPCs to bind excess antigen, since physiological inocula are often comprised of only a small 
number of infectious microbes 5. Instead, the most important role of MBCs may be to respond to 
pathogens that have antigenically changed since the first exposure, thereby evading pre-existing 
serum antibodies. Hapten-specific MBCs have fewer affinity-enhancing mutations than do 
LLPCs 6, 7, providing evidence that the repertoires of these two cell types do not fully overlap. 
Subsequent work demonstrated that pathogen-specific MBCs have distinct repertoires and 
distributions of epitope specificities relative to LLPCs 8, 9, 10. These findings led us and others to 
propose that the diversity of MBCs enables them to combat escape mutants and heterologous 
viruses better than do LLPCs 10, 11, 12. 
In theory, MBCs can respond to heterologous pathogens or escape mutants in two ways. 
First, the diversity of this compartment may be sufficient to allow the clonal selection of cross-
reactive MBCs without additional affinity maturation. Second, MBCs might re-initiate germinal 
centers (GCs) to shape new B cell receptors (BCRs) tailored to the second heterologous 
challenge. This decision is mediated principally by the subset of responding MBCs. In mice, 




protein ligand 2 (PD-L2). CD80+PD-L2+ MBCs preferentially differentiate into plasma cells 
upon antigen re-challenge, whereas MBCs lacking CD80 and PD-L2 expression differentiate into 
GC B cells 13. Though causally unrelated to isotype 13, 14, 15, 16, these subsets partially correlate 
with IgG versus IgM expression. CD80+PD-L2+ MBCs are enriched for IgG expression, while 
CD80-PD-L2- cells tend to express IgM. Accordingly, both in mice and humans, IgG+ MBCs 
preferentially differentiate into plasma cells after re-challenge, whereas IgM+ MBCs re-initiate 
GC reactions 3, 17, 18. While adoptive transfer, ex vivo culture, and transcriptional profiling 
experiments have established the differentiation potentials of these MBC subsets in isolation, it is 
challenging to define how these subsets act in concert and competition with one another in vivo, 
where serum antibodies and memory CD4+ T cells may modulate recall responses to 
heterologous antigenic challenges. Mouse studies using model antigens have reached differing 
conclusions on how efficiently MBCs re-initiate GCs and undergo secondary affinity maturation, 
as have human influenza studies 3, 14, 19, 20, 21. Resolving these differences experimentally is 
challenging, as there have been no reports of genetic tools that can distinguish the functional 
importance of secondary GC reactions versus clonal selection of pre-existing diversity without 
also altering other components of the immune response. 
Flaviviruses represent a particularly relevant system to differentiate between these 
possibilities. Pathogenic flaviviruses, such as West Nile (WNV), Japanese encephalitis (JEV), 
Dengue (DENV), and Zika (ZIKV) viruses co-circulate in similar geographic regions. Although 
primary flavivirus infections result in durable homotypic protection 22, in some instances, 
subsequent infections by heterologous flaviviruses can result in more severe symptoms than if 
the host were naïve 23, 24. The increased severity of heterologous secondary infections is mediated 




and effective vaccines for DENV have been challenging to develop. ADE is a process by which 
poorly or non-neutralizing antibodies generated after the first infection enhance uptake of the 
second heterologous virus in mononuclear phagocytes via Fcg receptors 25, 26, 27.  
The majority of flavivirus antibodies recognize epitopes on the envelope (E) protein 28. 
The E protein is divided structurally into three domains (DI, DII, and DIII) 29.  DII contains an 
immunodominant fusion loop (DII-FL) epitope that is recognized by poorly neutralizing 
antibodies and is conserved across flavivirus species 30, 31, 32, 33, 34. Antibodies that bind to the 
DII-FL epitope can thus recognize multiple flaviviruses and potentially mediate ADE. In 
contrast, DIII contains the lateral ridge (DIII-LR) epitope, which is recognized generally by 
flavivirus type-specific neutralizing antibodies 30, 35, 36, 37, 38, 39. Potently inhibitory antibodies that 
bind the DIII-LR epitope neutralize at a post-attachment step by preventing E protein dimer-
trimer transitions necessary for viral fusion 36, and protect against West Nile (WNV), Japanese 
encephalitis (JEV), Zika (ZIKV), and Dengue (DENV) virus infections in vivo.  Because of these 
data, the DIII-LR epitope is an attractive candidate for vaccine immunogen design.  
The DIII-LR epitope is less well-conserved at the sequence level across different 
flavivirus species. Therefore, resultant antibody responses are less cross-reactive and do not 
appear to cause ADE 40, 41. DIII-LR monoclonal antibodies (mAbs) that cross-react between 
DENV and ZIKV have been observed, but these antibodies are rare despite their evolution from 
a ‘public’ germline lineage 42, 43, 44. Notwithstanding this, it remains unknown whether polyclonal 
MBCs generated after one flavivirus vaccination or infection respond to the DIII-LR epitope of a 
subsequent heterologous vaccination or infection. If pre-existing MBCs could be used as a 
template for new specificities through secondary GCs, this would rationalize a strategy of 




individuals are already immune to at least one endemic flavivirus 45. In contrast, if recall 
responses were dominated by MBCs with little capacity to re-initiate new GCs, this might lead to 
weakly cross-neutralizing antibodies that could promote ‘original antigenic sin’ and ADE when 
faced with virus infections 23, 46, 47. In this latter case, immunogen design is warranted to avoid 
pre-existing MBCs and antibodies to minimize cross-reactivity and promote virus type-specific 
responses. 
To differentiate between these possibilities, we generated mice in which activation-
induced cytidine deaminase (AID), which mediates both class switching and somatic 
hypermutation 48, can be temporally deleted prior to the recall response. The lack of AID would 
prevent subsequent diversification or redirection of BCR specificity towards a heterologous 
antigenic target in secondary GCs.  Nonetheless, AID deletion minimally impacted recall 
responses against heterologous flavivirus antigen epitopes, suggesting clonal selection from a 
diversity of pre-existing MBC specificities with little role for further secondary affinity 
maturation towards heterologous antigens. This diversity is promoted by the selection of low 
affinity antigen-specific B cells that are continuously recruited into the MBC compartment. 
Restricting the initial diversity through immunogen design may allow for flavivirus type-specific 





MBCs do not require additional affinity maturation to respond to heterologous challenges. 
We previously demonstrated that MBCs are capable of recognizing a WNV mutant 
selected to escape neutralizing antibodies 10, 49. This mutation attenuates WNV infectivity and 
does not occur naturally. Thus, the mechanisms by which MBCs recognize neutralizing epitopes 
on naturally-occurring heterologous flaviviruses remains unexplored. To address this issue, we 
first developed a mouse model that allows for temporal abrogation of somatic hypermutation, 
and thus further affinity maturation, between primary and secondary challenges. Mice were 
generated with loxP sites flanking exon 2 of the Aicda gene (Figure 2.1A-B). Aicda encodes 
activation induced cytidine deaminase (AID), a protein that is critical for class switching and 
somatic hypermutation 48. These mice allow us to distinguish the contributions of secondary 
affinity maturation of MBCs versus clonal selection of MBCs with pre-existing specificities, as 
the former requires expression of AID whereas the latter does not.  
Aicdaf/f mice were crossed to a tamoxifen-inducible, hCD20-B cell specific Cre 
recombinase (TamCre) 50 (Figure 2.1A). To confirm deletion of AID at the protein level, Aicdaf/f 
x TamCre (AID cKO) mice were immunized with sheep red blood cells, treated with tamoxifen, 
and then GC B cells sorted at different time points after tamoxifen treatment. AID protein 
expression was abolished rapidly after tamoxifen treatment and remained undetectable by 
immunoblot for at least seven days (Figure 2.1C). To confirm loss of class switching after AID 
deletion, AID cKO and Aicdaf/f (AID WT) mice were treated with tamoxifen for two weeks, 
vaccinated against WNV using an inactivated veterinary vaccine, which generates similar 




days later (Figure 2.1D).  As expected, AID cKO mice failed to mount an isotype-switched IgG 
response to WNV DIII (Figure 2.1D).   
We next established a heterologous flavivirus immunization system to specifically 
monitor recall, but not primary antibody responses. WNV and JEV are related flaviviruses in the 
same serogroup and have DIII amino acid sequence similarity of approximately 75%. We thus 
employed Ixiaro, an alum-adjuvanted, clinically approved, inactivated JEV vaccine, which 
requires multiple immunizations to elicit a protective antibody response 51. Naïve mice 
challenged with Ixiaro generated few detectable JEV DIII-specific antibodies (Figure 2.2A). In 
contrast, JEV vaccination of WNV-immune mice resulted in an increase in JEV DIII-specific 
serum antibodies (Figure 2.2A).  Thus, JEV-DIII antibodies can be elicited efficiently in 
secondary heterologous recall responses.  
The importance of secondary affinity maturation of MBCs was determined by deleting 
Aicda between WNV and JEV challenges. AID WT and AID cKO mice were vaccinated with 
WNV and the primary response was allowed to proceed. Mice then were treated with tamoxifen 
56 days later to delete AID, and then re-vaccinated with JEV (Figure 2.2B). Serum antibody 
titers to WNV and JEV DIII proteins were then quantified by ELISA. We also monitored 
responses to recombinant DIII proteins carrying point mutations that ablate the LR epitope and 
abolish binding by potently neutralizing mAbs. For WNV DIII, we incorporated K307E and 
T330I mutations (KT DIII) 35, 36, whereas for JEV DIII we introduced 4 LR mutations 
(E306A/S329I/A366E/K390S, JEV ESAK-DIII)  based on previously solved structures 52. 
Proper reactivity and refolding of the JEV ESAK-DIII protein was confirmed by ELISA using 
the LR-specific neutralizing mAb JEV-31 37, and serum from immunized mice (Figure 2.3A). 




antibodies that bind both WT DIII and mutant DIII likely recognize a distinct non-LR DIII 
epitope, though a minority may remain DIII-LR-specific and tolerate the mutations.  
Deletion of AID prior to JEV booster vaccination had no discernible effect on serum IgG 
or IgM titers against WNV WT DIII, WNV KT DIII, JEV WT DIII, or JEV ESAK DIII between 
days 14-70 of the recall response (Figure 2.2C, Figure 2.3B-C). Recall responses were 
primarily directed against non-LR epitopes, as most antigen-specific antibodies bound WNV KT 
DIII and JEV ESAK DIII (Figure 2.2C). However, the levels of JEV WT DIII-reactive 
antibodies were higher than those against JEV ESAK DIII (Figure 2.2D). These data suggest 
that although most of the response is accounted for by WNV-JEV cross-reactive non-LR 
antibodies, a subset of the MBC response is directed against the neutralizing DIII-LR epitopes of 
both WNV and JEV. These responses were not affected by AID deletion (Figure 2.2D). 
Accordingly, deletion of AID also did not alter the serum neutralization response to JEV (Figure 
2.2E). These data demonstrate that rare pre-existing MBCs mediate cross-neutralizing responses 
without a requirement for further somatic hypermutation and affinity maturation upon 
heterologous flavivirus challenges.   
We considered the possibility that additional affinity maturation is necessary for more 
disparate heterologous challenges. ZIKV, another member of the flavivirus genus, shares ~ 55% 
DIII amino acid sequence similarity with JEV. We tetramerized recombinant ZIKV DIII to 
improve avidity, immunized mice, and then followed with JEV vaccination (Figure 2.2F). 
Deletion of AID prior to JEV booster vaccination in ZIKV DIII-immune mice did not impact 
IgG or IgM antibodies against ZIKV DIII, JEV DIII, JEV ESAK DIII, or LR-mutant ZIKV DIII 
(ZIKV AT DIII 38) (Figure 2.2G, Figure 2.3D-E). To determine if secondary affinity maturation 




DENV and ZIKV infection model (Figure 2.3F).  DENV2 and ZIKV DIII share approximately 
46% amino acid similarity. Analysis of ZIKV DIII-specific MBCs and LLPCs, after correcting 
for naïve B cell responses against ZIKV, again suggested a minimal role for secondary GC 
reactions and affinity maturation (Figure 2.3G).  These data demonstrate that for responses 
against both similar and disparate flavivirus DIII-LR antigens, for both vaccines and infections, 
secondary affinity maturation is minimally involved. Instead, heterologous challenges promote 
clonal selection from pre-existing cross-reactive MBCs expressing neutralizing antibodies.   
 
Plasma cell-biased MBCs recognize and respond to heterologous antigens. 
We next sought to define a cellular mechanism as to why secondary affinity maturation 
was not engaged in heterologous recall responses. The decision to initiate new GCs or plasma 
cells is largely determined by the responding MBC subsets, which are distinguished using a 
combination of IgM, IgD, CD80, CCR6, PD-L2, and CD73 as markers (Figure 2.4) 15, 17, 53, 54. 
PD-L2 and CD73 expression largely overlapped with CCR6 irrespective of immunoglobulin 
isotype (data not shown), suggesting redundancy between these markers. Thus, we focused 
subsequent analyses on CCR6 and CD80 expression. Antigen-specific MBCs in WNV-
vaccinated mice were identified using bacterially-expressed site-specifically biotinylated 
recombinant DIII assembled into tetramers with streptavidin-fluorophore conjugates (Figure 
2.4). Only the isotype-switched (swIg, IgM-IgD-) CD80+CCR6+ MBC subset was enriched for 
WNV DIII-specificity in vaccinated mice relative to unimmunized animals (Figure 2.5A).  
These CD80+ MBCs preferentially generate plasma cells upon re-encounter with cognate antigen 




Secondary affinity maturation plays a minimal role in recall responses to JEV, suggesting 
the existence of WNV-JEV cross-reactive MBCs prior to Ixiaro vaccination. Indeed, after 
primary vaccination with WNV, nearly half of WNV KT DIII-reactive MBCs recognized both 
JEV DIII-WT and JEV ESAK DIII (Figure 2.5B). These cells likely cross-react with conserved 
non-LR epitopes between DIII of WNV and JEV. In contrast, only ~1% of WNV DIII-LR-
specific MBCs also bound JEV DIII (Figure 2.5B). These data are consistent with previous 
studies reporting rare but detectable DIII-LR monoclonal antibodies that cross-react with 
different flavivirus species 37, 42, 43, 44. These data are also consistent with Figure 2.2D, in which 
the majority, but not all, of the response is directed against conserved DIII non-LR epitopes. 
Indeed, JEV vaccination of WNV-immune mice as in Figure 2.2A led a marked increase in 
WNV KT DIII-reactive antibodies (Figure 2.5C). Yet we detected only a very small frequency 
of WNV-DIII-specific GC B cells following JEV vaccination of WNV-immune mice (Figure 
2.5D), consistent with our observations that antigen-specific MBCs are mostly contained within 
the CD80+ plasma cell-biased subset (Figure 2.5A). These data suggest a minimal role for 
secondary GCs in recall responses to heterologous neutralizing DIII-LR epitopes. Instead, recall 
responses are dominated by pre-existing cross-reactive MBCs. 
 
MBCs are actively selected from GC B cells. 
Our data demonstrate that recall responses to heterologous flaviviruses in mice are 
restricted by the pre-existing MBC diversity, with little capacity to shape new specificities 
through secondary GCs. We therefore sought to define mechanisms by which this MBC diversity 
is generated during the primary response. Given the results above, we focused on mechanisms by 




random selection of GC B cells into the MBC compartment 55. This would result in similar 
distributions of antigen-specificities in both GC and MBC compartments. However, if active 
selection occurred, the antigen-specificity distributions between MBCs and GC B cells might 
differ.  
To distinguish these possibilities, wild-type mice were vaccinated against WNV and the 
DIII specificities in the GC B cell and MBC compartments were quantified by flow cytometry at 
different time points. GC B cells (CD19+GL7+CD38-IgD-) showed a skewed frequency of WNV 
DIII-reactive cells towards the LR epitope, although a small fraction of non-LR specific cells 
was present at stable frequencies throughout the experiment (Figure 2.6A). In contrast, MBCs 
were far less skewed towards the WNV DIII-LR epitope (Figure 2.6B), consistent with previous 
findings 10. The durable MBC population at late timepoints post-vaccination more closely 
mirrored the WNV DIII-LR and DIII non-LR frequencies at 1-2 weeks post-immunization than 
those at 3-4 weeks (Figure 2.6B). These data are consistent with a relatively early wave of MBC 
formation that contributes most of the durable memory population 7, and with the low lifespans 
of the highest affinity and somatically mutated MBCs 56, 57. MBCs had a larger ratio of WNV 
DIII non-LR:DIII-LR specificities than did GC B cells at all timepoints analyzed (Figure 2.6C).  
To confirm that WNV DIII non-LR specific GC B cells are more predisposed towards the MBC 
fate, we analyzed the frequency of CD38+CCR6+ MBC precursor cells for WNV DIII-LR and 
WNV DIII non-LR specific GC B cells (CD19+GL7+IgD-). CCR6 and CD38 expression mark 
both mature MBCs and GC precursors committed to the MBC fate 53, 58, 59. In the CD38+CCR6+ 
MBC precursor population, WNV DIII non-LR-specific cells were detected at greater frequency 
than WNV DIII-LR specific cells at all time points analyzed (Figure 2.6D). Thus, although the 




preferentially selected or maintained within the MBC compartment. The early emergence from 
the GC of WNV DIII-specific MBCs, especially those that are DIII non-LR specific, suggests 
that these cells likely underwent less affinity maturation and remained of low affinity, implying 
mechanisms as to why the MBC compartment is antigenically diverse.  
 
MBCs have lower avidity for their antigens than do LLPCs  
In both the hapten-response setting and in our results above, MBCs begin to exit GCs 
earlier than do bone marrow plasma cells 7, perhaps resulting in lower overall antibody affinity. 
Based on the number of somatic mutations, LLPCs are thought to be selected from high affinity 
GC B cells 7, 60, 61, 62, whereas MBCs are thought to be selected from low affinity GC B cells due 
to lack of T cell help 63. Thus, it is possible that an avidity threshold determines the MBC versus 
LLPC fate decision. A lowered avidity threshold, and therefore increased permissiveness to bind 
variant antigens, in turn could promote diversity in the MBC compartment. To determine if 
MBCs in our system have lower affinity or avidity for their antigen compared to LLPCs, we 
established methods to identify DIII-specific LLPCs and MBCs. Although plasma cells secrete 
most of their antibodies, we observed similar expression of surface Igk as by other B cells in the 
bone marrow (Figure 2.7A), consistent with previous studies 64.   We therefore used 
recombinant DIII tetramers to stain and sort single antigen-specific LLPCs and MBCs (Figure 
2.7A-B), cloned their V(D)J sequences into expression vectors, and then expressed and purified 
recombinant monoclonal antibodies (mAbs) 65.  The cloned mAbs from MBCs and LLPCs were 
specific for WNV DIII as determined by ELISA and biolayer interferometry. Analogous to the 
flow cytometry data, more than three times as many mAbs generated from cloned MBCs 




We first tested mAbs for their ability to bind monomeric WNV WT DIII. MBC-derived 
mAbs bound to monomeric WNV WT DIII similarly as did mAbs from LLPCs, with modest 
reductions in binding seen only at the highest concentration of antibody tested (Figure 2.8A). 
Reversing the orientation of a subset of the antibodies and WNV WT DIII on the ELISA plate to 
test affinity rather than avidity also failed to reveal differences between MBC- and LLPC-
derived mAbs (Figure 2.7C). To obtain data on binding kinetics of these mAbs, we performed 
biolayer interferometry (BLI). Affinities and on-rates again were similar between mAbs derived 
from MBCs and LLPCs (Figure 2.8B, Figure 2.7D). If anything, a small reduction in off-rates 
was observed in MBC-derived mAbs compared to LLPC-derived mAbs (Figure 2.7D). These 
data demonstrate that the B cell receptors (BCRs) of MBCs and of LLPCs bind monomeric DIII 
similarly. 
Given that WNV E proteins assemble into rafts of dimers on an icosahedral virion 66, we 
considered the possibility that LLPC-derived mAbs might bind native viral structures better than 
MBC-derived mAbs. To evaluate this, we  tested the avidity of the mAbs to WNV subviral 
particles (SVPs), which have similar icosahedral structures to fully infectious virions 67, 68. 
LLPC-derived mAbs bound with higher avidity to SVPs than MBC-derived mAbs (Figure 
2.8C). This result suggests that an avidity threshold for multimeric flavivirus antigens may 
distinguish MBC from LLPC selection in the GC and dictate the repertoire of antigens 
recognized.   
 
Absolute affinity thresholds do not segregate MBCs from LLPCs in vivo 
Our data are consistent with the existence of either an absolute affinity threshold that 




affinity B cells within a given GC are allocated to the MBC compartment, perhaps due to the 
differences in the timing of their selection 7. To determine if an absolute affinity threshold 
promotes the LLPC fate and results in a diverse MBC compartment in vivo, we utilized our 
Aicdaf/f x TamCre mouse model to freeze affinity maturation at different timepoints during the 
GC reaction. We first defined timepoints at which AID deletion abrogates affinity maturation but 
not class-switch recombination, and during which MBCs were formed but bone marrow plasma 
cells had not yet emerged.  This is important given differences in IgM and IgG signaling that can 
influence plasma cell selection 56, 67, 68, 69, 70, 71, 72.  At both 7 and 14 days after WNV vaccination 
in wild-type mice, the frequency of WNV DIII-specific GC B cells that had class switched was 
high (~90%, Figure 2.9A).  This is consistent with recent studies showing that class-switch 
recombination occurs prior to GC formation 73. In contrast, the number of somatic mutations in 
WNV DIII-specific GC B cells increased each week post-vaccination (Figure 2.9B), 
demonstrating ongoing affinity maturation.   
To determine the kinetics of accumulation of WNV DIII-specific bone marrow plasma 
cells, ELISPOT assays were performed at different time points after vaccination.   We found that 
WNV DIII-specific bone marrow plasma cells were detectable at 2 weeks post-vaccination and 
peaked 1 week later (Figure 2.9C), whereas MBCs emerged earlier (Figure 2.6B). We deleted 
AID at 1 or 2 weeks post-WNV vaccination to temporally abrogate affinity maturation and 
assessed the impact on MBC and LLPC numbers 8 weeks later (Figure 2.10A).  The frequencies 
of WNV DIII-LR and DIII non-LR specific MBCs were unaffected by AID deletion at weeks 1 
or 2 post-vaccination (Figure 2.10B). Cre expression alone also did not alter antibody responses 
to WNV WT DIII or WNV E protein (Figure 2.9D).  AID deletion at 1 week after vaccination 




reactive LLPCs relative to control mice (Figure 2.10C, Figure 2.9E). This may indicate an 
affinity threshold for plasma cell selection, but these data also could be explained by a reduction 
in the affinity of antibodies and resulting inability to detect all antigen-specific LLPCs. 
Consistent with the latter mechanism, deletion of AID 2 weeks after WNV vaccination did not 
affect serum antibody titers or the number of WNV DIII-specific LLPCs (Figure 2.10C, Figure 
2.9E). Moreover, serum antibodies bound equivalently to multivalent WNV SVPs irrespective of 
AID deletion (Figure 2.10D). IgM antibody responses against WNV were also unaffected by 
AID deletion (Figure 2.9F). Collectively, these data indicate that an in vivo absolute affinity 
threshold does not exist below which GC B cells are destined to become MBCs. These data are 
consistent with a recent study showing that AID-dependent affinity maturation is dispensable for 
LLPC and MBC formation 56. Notwithstanding this, our data do not exclude the existence of a 
relative affinity threshold that segregates MBC and LLPC specificities. 
 
Germline affinities of MBC antibodies are lower than those of LLPCs 
Previous studies using model antigens and BCR transgenic mice have demonstrated that 
MBCs and LLPCs of the same specificity have different affinities 7, 58, 60, 62, 63. Yet how 
differences in affinity would explain changes in specificities between MBCs and LLPCs in a 
polyclonal response is not immediately obvious. We first considered several affinity-independent 
mechanisms. One possibility is that distinct B cell subsets, such as marginal zone B cells, 
preferentially contribute to the MBC compartment. However, the antigen-specific precursor 
frequencies for DIII-LR and DIII non-LR were similar between marginal zone B cells and 
follicular B cells (Figure 2.11A). Furthermore, the V, D, and J genes used by our mAbs did not 




2.1). As repertoires of marginal zone B cells, B1 B cells, and follicular B cells are markedly 
distinct 74, these data argue against a mechanism by which distinct B cell subsets contribute to 
MBCs versus LLPCs. A second possibility is that MBCs emerge from precursors that are more 
self-reactive than LLPCs. Indeed, in human studies, MBCs tend towards self-reactivity 75, 76. 
However, we observed no changes in the ratios of DIII-LR and DIII non-LR during the transition 
from Hardy Fractions E-F (Figure 2.11C), during which self-reactivity is purged 77, 78, 79, 80, 81, 82. 
Although WNV DIII-LR cells in Fraction E displayed slightly lower surface levels of IgM, a 
marker of anergy and self-reactivity 80, than did WNV DIII non-LR specific cells, these lowered 
levels were not maintained in the recirculating mature Fraction F cells (Figure 2.11C). Thus, 
these avidity-independent mechanisms fail to explain how MBCs acquire specificities distinct 
from their LLPC counterparts. 
Another possible explanation is that the starting populations of B cells destined to 
become MBCs are distinct from and possess lower avidities than those of LLPC precursors. In 
this setting, a diverse set of MBC precursors, including those with weak binding to potentially 
poor epitopes such as DIII non-LR, are allowed to participate in the response. Indeed, B cells 
with immeasurably low affinities can participate in the response and contribute to MBCs 83, 84, 85, 
86. To test this possibility, we reverted somatic mutations in V(D)J regions from our mAbs back 
to their germline sequences and assessed their abilities to bind monomeric WNV WT DIII and 
WNV SVPs by ELISA. Germline-reverted MBC-derived mAbs bound more weakly (>10-fold) 
to WNV DIII and WNV SVPs than did germline-reverted LLPC-derived mAbs (Figure 2.12A). 
These data suggest that MBCs originate from relatively low avidity naïve B cells that are distinct 




Although MBCs have been proposed to be selected for low avidity from GCs 63, this does 
not preclude affinity maturation of their precursors. Indeed, mutation analysis of our panel of 
monoclonal antibodies indicate that MBCs have similar numbers of replacement mutations in 
their V(D)J genes as do LLPCs (Figure 2.12B).  MBC clones had in fact slightly greater 
numbers of silent mutations than did LLPCs, and the total number of mutations were similar 
between MBCs and LLPCs (Figure 2.11D).  Polyclonal IgH repertoire analysis during weeks 1-
4 of the response revealed reduced levels of somatic mutations in the MBC compartment relative 
to LLPCs, but only at weeks 3-4. For reasons that are unclear, the average number of mutations 
in the MBC population decreased somewhat after week 2, and the earlier week 1-2 timepoints 
better reflected the ultimate number of mutations observed in mAbs derived from week 8 MBCs 
(Figure 2.12B, 2.11E). These data provide further evidence that the durable pool of MBCs is 
formed early in the response 7. In both the MBC and LLPC compartments, affinity-matured 
antibodies bound better to monomeric WNV DIII than did their germline-reverted counterparts 
(Figure 2.12C). The extent of affinity maturation was difficult to calculate precisely, as many 
germline-reverted MBC mAbs bound antigen very poorly. A similar degree of affinity 
maturation was observed for binding to WNV SVPs (Figure 2.12D). Taken together, these data 
demonstrate that although B cells destined to become MBCs may be of low relative affinity, they 
still participate in GC reactions and substantially and rapidly improve their ability to bind 
antigen. 
 
MBCs are continuously committed from GCs. 
MBCs and LLPCs have distinct naïve precursor populations of differing avidities and 




unclear. Moreover, the selection of low affinity GC B cells into the MBC compartment is 
challenging to reconcile with the marked degree of MBC affinity maturation we observed in 
DIII-specific mAbs, resulting in many MBCs with nanomolar BCR affinities (Figure 2.8B).  We 
considered two explanations for these observations. First, it is possible that B cells become 
specified and committed to the MBC fate very early in the response, but still retain GC potential 
and transcriptional programs, and thus are allowed to affinity mature.  Second, it is possible that 
MBC commitment occurs continuously from GCs, which, based on BrdU pulse-chase data, 
likely occurs over the first few weeks of the response 7.  Thus, as GCs improve their overall 
affinities over time, so too does the pool from which MBCs are selected. In this second 
mechanism, evidence of early MBC specification would be observed within the main body of 
GCs in addition to the fully-committed MBC precursors. To distinguish between these 
possibilities, we first performed single cell RNA sequencing of WNV DIII-specific mature GC B 
cells, which are marked by EphrinB1 expression (Figure 2.13A) 87, and examined cells with 
both GC and MBC transcriptional signatures.   
Uniform Manifold Approximation and Projection (UMAP) analysis of the data revealed 
five transcriptional clusters (Figure 2.14A) that segregated independently of cell cycle genes 
(Figure 2.13B). Clusters 0, 1, 2, and 4 contained cells expressing Aicda, Bcl6, Jchain, Cxcr4, 
Foxo1, and Cd86 and thus represent mature GC B cells with light zone and dark zone signatures 
(Figure 2.14B, Figures 2.13C-D). Cluster 3 lacked Aicda expression and instead expressed high 
levels of CD38, which marks EphrinB1+ MBC precursors 87.  We further confirmed that cluster 3 
is enriched in genes associated with MBC commitment (Figure 2.14C), including Zbtb32 13, 88, 
89, Bach2 63, Il9r 89, Klf2 89, and Ccr6 58. This cluster expressed low levels of S1pr2 (Figure 




2.14D), which are associated with GC egress 90, 91. This transcriptional profile of MBC 
precursors argues against their potential to continue to participate in GCs and affinity mature.   
The MBC genes Zbtb32, Il9r, Klf2, and Ccr6 also were expressed by some cells 
throughout clusters 0, 1, 2, and 4 and were co-expressed with Aicda and Jchain (Figure 2.14B-
C). Unlike cluster 3, clusters 0, 1, 2, and 4 express high levels of S1pr2 and low levels of Gpr183 
and S1pr1, indicating GC retention, implying that these cells can still participate in GC reactions 
(Figure 2.14D). These data suggest that cells with intermediate levels of MBC specification and 
commitment might precede MBC precursor generation from the GC.   
To functionally test whether committed MBC precursors continue to participate in GCs 
or are formed de novo from GCs, we designed a lineage tracing model. We noted that MBC 
precursors, but not other GC B cells, lack expression of Jchain (Figure 2.14B), a BLIMP1-
dependent marker of plasma cell potential 92, 93. We thus generated mice carrying an IRES-
CreERT2 cassette in the 3’ UTR of Jchain and crossed them to animals with a ROSA26-loxP-
stop-loxP TdTomato cassette (TdT-Jchain mice). Tamoxifen treatment of these mice revealed 
efficient labeling of GC B cells and LLPCs, with negligible labeling of other B cells or non-B 
lineages (Figure 2.13E). We reasoned that at early timepoints post-vaccination, tamoxifen 
treatment would preferentially mark GC B cells but leave MBC precursors mostly unlabeled. If 
MBCs at later timepoints remained similarly unlabeled, these data would imply that low affinity 
MBC precursors are committed early in the response yet continue to participate in GC reactions 
(Figure 2.13F). In contrast, if the percentage of labeled mature and precursor MBCs at later 
timepoints were substantially higher than early in the response, this would imply that MBC 
commitment is not complete early in the response (Figure 2.13F). To test these models, TdT-




vaccination, and TdTomato expression analyzed in DIII+ GCs, MBC precursors, and swIg 
MBCs at different time points (Figure 2.14E).  Antigen-specific GCs were efficiently labeled, 
remaining above 60% TdTomato+ at both weeks 1 and 4 post-vaccination. In contrast, DIII+ 
MBC precursors were fully unlabeled at Day 7, but increased over time to approach that of GCs 
by Day 28 (Figure 2.14F).  Because the total number of antigen-specific MBC precursor cells 
was very low at Day 7, we also examined the labeling frequency of polyclonal MBC precursors. 
This was also quite low at Day 7 (6.5%), confirming the lack of Jchain expression in these 
population of cells. At 28 days post vaccination, the frequency of labeled mature MBCs was 
similar to the frequency of labeled MBC precursors (Figure 2.14F).  These data argue against 
prolonged participation in GCs by unlabeled and committed MBC precursors. Instead, these 
results suggest that MBCs are specified and selected for relatively low affinity from GCs de novo 
for at least the first few weeks of the response, which allows for their marked increase in affinity 





Unlike LLPCs, MBCs can respond to antigen re-exposure by rapid proliferation and 
differentiation to either plasma cells or secondary GC B cells, the latter of which can produce 
new affinity-matured plasma cells and MBCs. These recall responses may be of particular 
importance when mutants or genetically divergent strains of pathogens arise that escape serum 
antibodies. Examples of such pathogens include HIV, which mutates continuously during 
chronic infections; influenza viruses, which undergo antigenic drifts and shifts; and flaviviruses, 
in which related but genetically distinct strains and serotypes co-circulate in overlapping 
geographic regions. For each of these pathogens, efforts are underway to design vaccine 
immunogens that would focus the antibody response to neutralizing epitopes. As an example, 
sequential immunizations are envisioned in which MBCs are gradually guided to the target 
antibody specificities that bind to antigens such as the CD4-binding site epitopes on HIV 94, 95, 96. 
This strategy assumes the ability of immunogens to engage MBCs to re-initiate GC reactions. 
Yet in mouse models of heterologous flavivirus challenges, we observed that the MBC 
compartment was largely static after the primary vaccination or infection, with little ability to 
generate new specificities through secondary GCs. Similar conclusions were reached in recent 
influenza studies in both humans and mice 19, 97. Thus, the underlying MBC biology may limit 
the success of sequential immunization strategies. Clearly more details are needed on the cues 
that allow for the generation and engagement of MBC subsets that can form secondary GCs.  
MBCs are diversified relative to LLPCs to ensure greater antigenic coverage than can be 
achieved by serum antibodies alone. Recent studies on responses to model antigens have 
provided some potential mechanistic explanations for this property. MBC commitment in GCs 




highest avidity cells in the GC receive sufficient T cell help to exit as LLPCs 60, 62. In an 
alternative model, signals in the GC may preferentially promote MBC commitment early and 
switch to LLPC selection later in the response, thereby explaining differences in final avidity 7, 
98. Our findings on flavivirus-specific responses agree with and extend upon aspects of both 
these models. First, we observed an early wave of formation that contributes to most of the 
durable MBC population 7.  Second, we observed a lower average final avidity of MBCs relative 
to their LLPC counterparts 6, 7, 58, 63.  This result, along with observed differences in MBC 
specificities relative to GCs throughout the response, argue in favor of active selection 63. Yet the 
extent of MBC affinity maturation we observed was substantial and similar to that of LLPCs. 
Instead, the germline precursor avidities were lower in MBCs relative to LLPCs, perhaps 
explaining the differences in final avidities. Unlike responses to haptens or those observed with 
BCR transgenics where single mutations impart large increases in avidity, polyclonal responses 
against protein antigens affinity mature more gradually 99, 100. Thus, a low starting binding 
capacity may predispose to low final avidities and bias toward the MBC fate either through an 
active selection mechanism, by limiting persistence in GCs before signals switch to promote 
LLPCs, and/or by preferentially selecting MBC clones that improve affinities very rapidly prior 
to this switch.  
Low relative affinities could increase the breadth of MBC specificities and contribute to 
recall responses in several ways. First, the low relative binding capacity of MBCs might allow 
for affinity maturation in reverse, in which mutations in a pathogen in fact enhance recognition 
by a subset of MBCs. Our previous work in fact revealed some evidence of such anticipatory 
memory 10. Second, a low avidity threshold might allow for a greater clonal diversity of MBC 




that immunogen interactions with germline precursors can be manipulated to increase or 
decrease final MBC and antibody diversity. This agrees with studies that have found other B cell 
properties, such as proliferation, survival, and GC entry to be linked to germline affinity 57, 61, 101, 
102, 103, 104, 105, 106. 
For flavivirus vaccines, the best strategy might be to restrict antibody and MBC diversity 
to minimize weakly cross-neutralizing antibodies and ADE, as we found no evidence that such 
antibodies could be redeemed through secondary GC reactions. DENV and ZIKV DIII-LR cross-
reactive monoclonal antibodies with ‘public’ clonotypes have been isolated from humans 42, 44, 
and JEV-WNV cross-reactive DIII-LR antibodies were observed both in our study and in 
previous work 37. Our data suggest that such cross-neutralizing antibodies are likely rare, reactive 
across only highly related strains, and may already exist prior to heterologous infections. As 
corroborating evidence, heterologous DENV and ZIKV infections do not measurably alter the 
pre-existing MBC pool in humans 107.  
Structure-based immunogen design to minimize cross-reactive responses, even to 
otherwise neutralizing epitopes, may achieve flavivirus type-specific immunity while minimizing 
ADE. Several such efforts are underway already 108, 109, 110, 111, yet our study offers some 
additional insight. First, a ‘hidden’ repertoire of low affinity MBCs exists that is not necessarily 
reflected in serum antibodies. These MBCs potentially can cross-react with conserved non-
neutralizing epitopes across flaviviruses, such as DIII-non-LR and thus yield ADE-promoting 
antibodies. Given that much of the target population for flavivirus vaccines is seropositive for at 
least one flavivirus already, special attention might be needed to avoid pre-existing MBCs via 
immunogen design. Second, for naïve individuals, immunogen multimerization and engineering 




strategy to limit the initial MBC diversity and focus the primary response on potently 
neutralizing epitopes 112. Similar strategies have shown initial promise in models of HIV 





2.5 Materials and Methods 
Mice.  All animal procedures used were approved by the Animal Care and Use Committees at 
Washington University and the University of Arizona. WNV and JEV infections were 
performed according to A-BSL3 standards. All mice were housed and bred in pathogen-free 
facilities.  C57BL6/N mice were obtained from the National Cancer Institute.  Aicdaf/f mice 
were generated by injecting targeted C57BL/6N embryonic stem line (HEPD0615_4_B08, 
Aicdatm1a(EUCOMM)Hmgu, European Conditional Mouse Mutagenesis Program) into B6 albino 
(Jackson Laboratory) mice by the Transgenic Knockout Microinjection Core facility at 
Washington University in St. Louis.  Pups were first crossed to ROSA26::FLP2 (Jackson 
Laboratory, Stock No: 008463) mice to remove the LacZ and neomycin resistance 
sequences, and then to hCD20-TamCre mice 50 to generate Aicdaf/+ mice. Mice were then 
maintained as either Aicdaf/f or Aicdaf/f/x hCD20-TamCre and littermates were used as controls. 
The following primers were used for genotyping the Aicda allele: common forward 5’- 
AGCCCCTCAGCCCTTTAATC-3’, wild-type reverse 5’- AGCTGGTGTTGTGTGCGAAG-
3’, Aicda targeted 5’- TCGTGGTATCGTTATGCGCC-3’. JchainCreERT2 mice were 
generated by microinjecting Cas9-gRNA ribonucleoparticles into C57BL6/J zygotes alongside 
an IRES-CreERT2 donor cassette targeting the 3’ UTR of Jchain. Targeted mice were crossed 
to C57BL6/N mice and then to LoxP-Stop-LoxP (LSL)-TdTomato mice (Jackson Laboratory, 
Stock No: 007914).  Mice heterozygous for Jchain and LSL-TdTomato were used.  Tamoxifen 
treatment consisted of placing mice on tamoxifen for two weeks.  For timed deletions, mice 
were also gavaged for two consecutive days with 50 ug of tamoxifen dissolved in corn oil per 





DIII refolding and biotinylation 
To generated biotinylated DIII, DIII sequences were cloned downstream of a modified pET21 
expression vector containing 6x Histidine tag, AviTag (GLNDIFEAQKIEWH), and Thrombin 
cut site 36. WNV, ZIKV and JEV DIII proteins were refolded by oxidative refolding as 
previously described 30, 37, 38.  Briefly, BL21(DE3) E. coli cells were used for autoinduction of 
DIII cloned into the pET21 expression vector. The DIII protein was refolded from inclusion 
bodies by oxidative refolding and purified by size exclusion.  AviTagged DIII protein were 
biotinylated using the NIH Tetramer Core Facility biotinylation protocol 
(https://tetramer.yerkes.emory.edu/support/protocols#9).   
 
Flow cytometry.   
Single cell suspensions were prepared from bone marrow or spleen. Erythrocytes were lysed 
using an ammonium chloride-potassium solution, and lymphocytes were isolated with 
Hisopaque-1119 (Sigma-Aldrich) and density gradient centrifugation. Cells were resuspended in 
PBS with 5% adult bovine serum and 2 mM EDTA prior to staining with antibodies and labeled 
DIII-tetramers. The following antibodies were purchased from Biolegend: 6D5 (CD19)-Alexa 
Fluor 700; GL7-FITC -PerCP-Cy5.5, - PE, or Pacific Blue; 90 (CD38)-BV510 or -APC-Cy7; 
281-2 (CD138)-PE or -APC; RMM-1 (IgM)-APC; 11-26c.2a (IgD)-PerCP-Cy5.5, -PE-
Dazzle594, -BV510, or -BV605; 16-10A1 (CD80)-PE, -Alexa Fluor 488, or -Brilliant Violet 
421; TY25 (PD-L2)-Brilliant Violet 421 or -PE-Dazzle594; TY/11.8 (CD73)-APC-Cy7; B3B4 
(CD23)-BV510; and RA3-6B2 (B220)-FITC.  The following antibodies were purchased from 
eBioscience: 11/41 (IgM)-PerCP-e710 and 4E3 (CD21/35)-FITC. Ephrin-B1-biotin was 




(CD11b), 2C11 (CD3), GK1.5 (CD4), 53-6.7 (CD8), and TER119. Labelled DIII tetramers were 
generated by incubating biotinylated DIII with labelled streptavidin (Brilliant Violet 421, 
Brilliant Violet 605, PE, or APC, all from Biolegend) at a 1:4 molar ratio, where 1/10th of the 
total streptavidin was added to DIII every 10 minutes. DIII tetramers were diluted in PBS to 130 
ug of DIII/mL, and cells were stained at 2.6 ug/mL of DIII tetramer per 107 cells for 20 min on 
ice.  Antigen-specific MBCs and GC B cells were enriched by depleting non-B cells, IgM+ and 
IgD+ splenocytes cells by cellular panning. Splenocytes were stained with rat anti-CD4, CD8, 
CD11b, CD3, Ter119, IgM, and IgD on ice for 20 min, wash, and then incubated on plates pre-
coated with 1 ug/mL of mouse anti-rat IgG (3053-01, Southern Biotech) for 20 min at 4°C. The 
non-adherent cell fraction was collected, washed, and then stained with MBC and GC B cell 
surface markers (CD19, GL7, CD38, CD80, CCR6 and DIII tetramers).  Antigen-specific bone 
marrow plasma cells were subjected to CD138 enrichment prior to DIII-tetramer staining. Total 
bone marrow cells were stained with 2 uL of anti-CD138 APC, cells washed and then stained 
with anti-PE magnetic beads (0.5 uL/107 cells, Miltenyi Biotec). Positive enrichment of CD138-
expressing cells was performed using MACS LS columns (Miltenyi Biotec), where enriched 
cells were stained with 2.6 ug/mL of DIII tetramers.   
 
ELISA.   
ELISA plates (9018, Corning) were coated overnight at 4°C in 0.1 M sodium bicarbonate buffer, 
pH 9.5 containing 5 ug/mL of the appropriate domain III antibody, WNV E protein, or 4G2 
mAb. All other incubation steps were performed at room temperature for 1 hour.  Wash steps 
were performed between each step using PBS + 0.05% Tween-20.  Plates were blocked with 




incubated with media containing WNV SVPs.  Serum was probed with 0.1 ug/mL of biotinylated 
anti-mouse IgG (715-065-151, Jackson ImmunoResearch Laboratories) or 0.14 ug/mL of 
biotinylated anti-mouse IgM (115-065-075, Jackson ImmunoResearch Laboratories) and then 
detected with streptavidin conjugated horseradish peroxidase (554066, BD biosciences).  MAbs 
were probed with 0.8 ug/mL of peroxidase conjugated anti-human IgG (709-035-149, Jackson 
ImmunoResearch).  Plates were developed using TMB (J61325, Alfa Aesar) and neutralized with 
2N H2SO4.  Optical density (OD) values were measured at 450 nm. Serum endpoint titer was 
defined as the inverse dilution factor that is three standard deviations above background using 
variable slope measurements and Prism software (GraphPad Software).  OD  values from mAbs 
were normalized to the OD values of humanized E16 (NR-31082, BEI Resources) at each 
dilution.   
 
Neutralization Assays. 
Serum was heat-inactivated at 56°C for 30 min. Serial dilutions of serum or mAbs were 
incubated with 100 FFU of WNV-NY99 or JEV SA14-14-2 for 1 h at room temperature.  
Serum/mAbs-virus complexes were added to a monolayer of Vero cells in a 96-well plate and 
incubated at 37°C with 5% CO2 for 1 h. Cells were overlaid with 1% (w/v) 
carboxymethycellulose in MEM supplemented with 2% FBS, 1x Pen-Strep, and 1x GlutaMax. 
Plates were harvest 24 (WNV) or 36 (JEV) h later and fixed with 1% PFA in PBS. Plates were 
incubated with 500 ng/mL of hE16 (for WNV) or JEV-31 (Fernandez, E. et al., mBio, 2018) 
diluted in PBS + 0.1% saponin+0.1% BSA. hE16 was detected using 0.8 ug/mL of peroxidase 




mouse IgG followed by streptavidin-HRP.  Foci were visualized using TrueBlue peroxidase 
substrate (50-78-02, KPL) and enumerated on the CTL ImmunoSpot S6 Analyzer.   
 
ELISpot Assays.   
ELISpot plates (MSHAN4510, Millipore Sigma) were coated with 10 ug/mL of anti-mouse Ig 
kappa (559749, BD biosciences) in PBS overnight at 4°C. Plates were blocked with complete 
DMEM for 1 h. Bone marrow plasma cells were enriched on CD138 as described above and 
plated in triplicates. Cells were incubated at 37°C with 5% CO2 for 16 h.  Plates were washed 
with PBS followed by PBS+0.05% Tween-20, incubated with 5 ug/mL of biotinylated WNV WT 
or KT DIII diluted in PBS, 2% adult bovine serum and 0.05% Tween-20 and incubated at room 
temperatures for 1 h. Plates were rinsed with PBS + 0.05% Tween-20 and then incubated with 
streptavidin HRP diluted in PBS, 2% adult bovine serum, and 0.05% Tween-20 at room 
temperatures for 1 h. Wells were washed one last time with PBS + 0.05% Tween-20 and PBS. 
Spots were developed using TrueBlue peroxidase substrate and enumerated on the CTL 
ImmunoSpot S6 Analyzer.  The total number of DIII-specific bone marrow plasma cells was 
calculated by multiplying the number of enumerated spots by the plating dilution factor. The 
value was then divided by the total number of bone marrow cells.  
 
WNV SVP production. 
Lenti-X 293T cells were transfected with WNV prM-E construct 115 using GeneJuice transfection 
reagent.  Supernatants were collected 48 h later, filtered using a 0.2 um filter, aliquoted, flash 





Immunizations.   
Mice were administered two doses of inactivated WNV Innovator vaccine (Valley Vet Supply) 
by intraperitoneal injection on days 1 and 2 10.  Biotinylated ZIKV WT 38 and A310/T335 (LR 
mutant) DIII were tetramerized with streptavidin at a 1:4 molar ratio, where 50 ug of tetramer 
was mixed with 100 uL of AddaVax vaccine (Invivogen) and then administered to mice by 
intraperitoneal injection.   
 
MAb generation and purification.   
Antigen-specific MBCs were sorted using a FACSAria II and cultured as previously described 10. 
Briefly, each well of a 96-well plate were seeded with 30,000 mitomycin C-treated BAFF + 
CD40L + NIH 3T3 cells 10, one day prior to seeding individual MBCs. Sorted MBCs were co-
cultured with the feeder cells in the conditioned 3T3 complete DMEM medium (DMEM, 10% 
FBS, 1x penicillin-streptomycin, 1 mM sodium pyruvate, 1x nonessential amino acids, and 2 
mM GlutaMax) containing 1 µg/ml pokeweed mitogen lectin (Sigma-Aldrich), 10 µg/ml 
lipopolysaccharide (from E. coli 0.111:B4; Sigma-Aldrich), 1 µg/ml phosphorothioated murine 
CpG (5′-TCCATGACGTTCCTGATGCT-3′; Integrated DNA Technologies), 16 ng/ml mIL-2, 
10 ng/ml mIL-6, 17 ng/ml mIL-10 (PeproTech), 10 mM HEPES, and 50 µM β-mercaptoethanol). 
Supernatant was collected after 6 days of culture, and DIII specificity assessed by ELISA. V(D)J 
sequences were amplified as described in (Tiller, 2009) and cloned into modified heavy 
(Addgene plasmid # 8079) and light chain (Addgene plasmid # 80796) expression vectors 116.  
The modified heavy chain expression contains a G4S linker sequence and an AviTag sequence at 
the 3’ end of the hIgG1 sequence. Single antigen-specific LLPCs from the bone marrow were 




V(D)J sequences were isolated according to a previously published protocol 118. Briefly, cDNA 
was generated, two rounds of nested PCRs performed to amplify the V(D)J sequences, and then 
V(D)J sequences cloned into the modified heavy and light chain expression vectors.   
 
Lenti-X 293T cells (Clontech) used for transfections were maintained in complete DMEM 
containing 10% ultra-low IgG FBS (ThermoFisher), 1x penicillin-streptomycin, 1 mM sodium 
pyruvate, 1x nonessential amino acids, and 2 mM GlutaMax.  Transfections were performed 
using GeneJuice (EMD Millipore Novagen). Somatically hypermutated mAbs were produced by 
co-transfecting heavy chain construct, light chain construct, and a BirA ligase construct. 
Germline reverted mAbs were produced by co-transfecting heavy and light chain constructs. 
Fresh media was supplemented every other day. Six days after transfection, supernatants were 
collected, cellular debris filtered, and then mixed with Protein G IgG Binding Buffer (Thermo 
Scientific) at a 1:1 ratio.  MAbs were purified from the supernatant by Protein G (GE Life 
sciences) affinity chromatography. Purified antibodies were concentrated and buffer exchanged 
with PBS containing 0.1% sodium azide using an Amicon® Ultra-15 Centrifugal Filter Unit (30 
kDa membrane).   
 
BLI Binding Assays.  
The binding affinity of affinity matured mAbs to WNV WT DIII was assessed by BLI using an 
Octet Red384. The buffer used contained 150 mM NaCl, 10 mM HEPES, 3 mM EDTA, 0.005% 
Tween20, and 1% BSA, pH 7.4.  Biotinylated mAb was loaded onto streptavidin biosensors 




DIII was measured at 30°C.  Data were analyzed using the ForteBio DataAnalysis 11.0 software, 
and fitted to a 1:1 binding model.   
 
Single cell RNA-seq. 
WNV DIII-specific GC B cells (CD19+GL7+EphrinB1+IgD-) were sorted using a FACS AriaII 
and prepared and processed according to 10x Genomics instructions for Single Cell Protocols 
Cell Preparation Guide and Chromium Single Cell V(D)J Reagents kit.  Sequencing files were 
processed using the CellRanger program (10x Genomics), where minimum read cutoffs were 
kept at default settings. Sequences were further processed and visualized using Seurat 119, 120. 
Cells containing more than 5% mitochondrial genes were discarded. UMAP clusters of cells 
were determined based on global gene expression or on cell cycle genes.   
 
GC mutation analysis.  
WNV DIII-specific GC B cells (CD19+GL7+IgD-CD38-) from WT mice. were sorted 7, 14, 21, 
and 28 days after WNV vaccination. RNA was using the NucleoSpin RNA XS kit (Macherey-
Nagel) per manufacturer’s instructions. cDNA synthesis was performed as previously described 
118.  IgG immunoglobulin transcripts were amplified with the following primers: msVHEstdseq1 
5’- 
ACACTCTTTCCCTACACGACGCTCTTCCGATCTGGGAATTCGAGGTGCAGCTGCAGG
AGTCTGG-3’ and commonCgstdseq2 5’-
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTCARKGGATRRRCHGATGGGG-3’.  
A final amplification with P5 forward Stdseq1 and P7 reverse Stdseq index primers were used as 




Miseq v3 2x250 platform using previously published 121.  Forward and reverse reads were paired 
using the default settings of PEAR 122. Paired reads were further analyzed using Migmap 
(https://github.com/mikessh/migmap) where full length VDJ sequences were merged and 
corrected for PCR errors. Somatic hypermutation information was extracted using the Migmap 
post-analysis command.   
 
Immunoblotting. 
Aicdaf/f TamCre and Aicdaf/f mice were immunized with 8x108 sheep red blood cells (Lampire) 
by intraperitoneal injection. GC B cells were sorted on a FACS Aria II at different timepoints 
after immunization. Cells were lysed in Laemmli buffer containing 2% SDS and 5% 2-
mercaptoethanol and stored at -20°C until analysis. Cell lysates were separated by 10% SDS-
PAGE and transferred to PVDF membrane (Roche). The membranes were probed with 20 ug/mL 
of anti-AID monoclonal antibody (mAID-2, eBioscience).  The signal was detected using a 
Luminata HRP substrate (Millipore). Signal from the horseradish peroxidase was quenched by 
incubating the membrane with 30% H2O2 for 10 min. The membrane then was probed with anti-
ERK2 (Santa Cruz, C-14) antibody as a loading control. The signal was detected using a 
Luminata HRP substrate.   
 
Statistics. 
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Figure 2.1 Validation of Aicda f/f mice.  
(A) Targeting construct for Aicda. (B) PCR genotyping of the Aicda allele to confirm targeting 
and absence of neomycin resistance cassette. (C) Aicdaf/f x TamCre mice were immunized 
with sheep red blood cells and treated with tamoxifen starting on day 7 after immunization. 
CD19+GL7+ cells were sorted at different days after tamoxifen and immunoblotted for AID. 
ERK2 level (probed with anti-ERK2 antibody) was used as the loading control. (D) Aicdaf/f x 
TamCre mice were treated with tamoxifen for two weeks and then immunized with the 
inactivated WNV vaccine.  Serum was collected 12 days later to confirm absence of anti-






Figure 2.2 MBCs do not require additional affinity maturation to respond to 
heterologous flavivirus challenges.  
(A) WNV-vaccinated and naïve mice were bled before (D0) and 14 days after JEV 
vaccination. Serum IgG endpoint titers against JEV WT DIII were calculated as the reciprocal 
serum dilution that was three standard deviations above background. Endpoint titers were 
calculated as the reciprocal serum dilution that was three standard deviations above 
background.  Each symbol represents an individual mouse.  **p < 0.01; paired student’s t-test.  
Data comes from one experiment.  (B) Schematic representation of the experimental setup for 
WNV vaccination and JEV recall responses. (C) Serum from WNV-immune Aicda f/f x 
TamCre (AID cKO) and Aicda f/f (AID WT) was collected 70 days after JEV vaccination. 
Levels of WNV DIII- and JEV DIII-specific IgG were measured by ELISA.  Mean endpoint 
titers ± standard error of the mean (SEM) are shown. Each symbol represents an individual 
mouse. (D) IgG levels, shown as OD450nm values for 1:50 diluted serum, collected in (C), for 
binding to JEV WT and JEV ESAK DIII.  Each symbol connected by lines represents paired 




Neutralizing antibody titers (1/IC50) to JEV were measured by a focus reduction 
neutralization test (FRNT) from serum collected in (C).  Mean ± SEM are shown; each symbol 
represents an individual mouse. (F) Schematic representation of the experimental setup for 
ZIKV DIII immunization and subsequent JEV recall responses. (G) Serum from ZIKV DIII-
immunized AID cKO and AID WT was collected 28 days after JEV vaccination. Levels of 
ZIKV DIII and JEV DIII specific IgG antibodies were measured by ELISA. Mean endpoint 
titers ± SEM are shown. Each symbol represents an individual mouse.  Data are pooled from 







Figure 2.3 IgM responses after heterologous JEV vaccination.   
(A) Validation of JEV ESAK DIII by ELISA. JEV DIII-LR specific mAb JEV-31 37 was used 
to confirm loss of the LR epitope. Wild-type mice were immunized with JEV ESAK DIII, and 
immune serum was used to probe for binding to JEV WT and ESAK DIII.  Data from 1 
experiment is shown.  Mean values ± SEM are shown.  (B) Serum from WNV-immune Aicda 
f/f x TamCre (AID cKO) and Aicda f/f (AID WT) was collected before, 14 and 28 days after 
JEV vaccination. Levels of JEV WT DIII and JEV ESAK DIII specific IgG antibodies were 
measured by ELISA.  Endpoint titers were calculated as the reciprocal serum dilution that was 
three standard deviations above background.  Mean endpoint titers ± SEM are shown. Each 
symbol represents an individual mouse where matched samples are connected by a line.  Data 
is from one experiment.  (C) Serum from WNV-immune AID WT and AID cKO mice was 
collected ten weeks after JEV vaccination.  JEV WT and JEV ESAK DIII specific IgM levels 
are shown as the OD450nm values from serum diluted 1:50.  Each symbol represents an 
individual mouse.  Mean ± SEM are shown.  Data are pooled from two independent 




before and 28 days after JEV vaccination.  Levels of JEV WT DIII and JEV ESAK DIII 
specific IgG antibodies were measured by ELISA.  Endpoint titers were calculated as the 
reciprocal serum dilution that was three standard deviations above background.  Mean 
endpoint titers ± SEM are shown. Each symbol represents an individual mouse where matched 
samples are connected by a line.  Data are pooled from two independent experiments. (E) 
Serum from ZIKV-immune AID WT and AID cKO mice was collected four weeks after JEV 
vaccination.  JEV WT and JEV ESAK DIII specific IgM levels are shown as the OD450nm 
values from serum diluted 1:50. Data are pooled from two independent experiments.  (F) 
Schematic representation of DENV and ZIKV recall responses. (G) The frequency of ZIKV 
DIII-specific MBCs and LLPCs were quantified by flow cytometry and ELISPOT, 
respectively. Mice challenged with only ZIKV were used to delineate the naïve B cell 
responses. AID WT (2° only) is calculated by subtracting the average WT primary response 
value from the AID WT (1° and 2°) values.  Mean values ± SEM are shown; each symbol 







Figure 2.4  Gating strategy for memory B cell subsets.    
Gating strategy for MBC subsets based on CD80 and CCR6 expression. Cells are gated on 
CD19+GL7- and IgM+IgD+, IgM+IgD-, or swIg (IgM-IgD-) expression. Representative data 






Figure 2.5 Plasma cell-biased MBCs recognize and respond to heterologous antigens. 
(A) Mice were vaccinated with inactivated WNV vaccine and the number of DIII-specific 
cells in different MBC subsets was calculated by flow cytometry 8-12 weeks later. WNV-
vaccinated mice are compared to naïve animals. Mean ± SEM are shown; each symbol 
represents an individual mouse. Data are pooled from two independent experiments.  *p < 
0.05; student’s two-tailed t test for each subset. (B) Representative flow cytometry plots 
showing the cross-reactivity of WNV DIII-LR and WNV DIII non-LR cells to JEV DIII-LR 
and JEV DIII non-LR cells. WNV DIII-binding cells were enriched from 5 pooled spleens 
from WNV-vaccinated mice and then probed for JEV WT and ESAK DIII reactivity. (C) Sera 
from WNV-immune mice, collected in Figure 1A, were assessed for WNV WT and WNV KT 
DIII binding before (D0) and 14 days post JEV vaccination.  Endpoint titers were calculated as 
the reciprocal serum dilution that was three standard deviations above background. Each 
symbol represents an individual mouse.  **p < 0.01; matched two-way ANOVA.  Data comes 
from one experiment.  (D) The frequency of WNV DIII-specific GC B cells (CD19+GL7+IgD-
CD38-) 7 and 14 days after JEV vaccination of WNV-immune mice was quantified by flow 
cytometry. A representative plot of DIII-specific GC B cells is shown on the left and 
quantified on the right.  Mean ± SEM are shown; each symbol represents an individual mouse.  






Figure 2.6 MBCs are actively selected from GC B cells.  
(A) Mice were immunized with WNV inactivated vaccine and DIII-specificities in GC and 
MBC compartments were enumerated by flow cytometry at days 7, 14, 21, 28 and 56+.  A 
representative plot of DIII-specific GC B cells is shown on the left and quantified on the right.  
Mean frequencies ± SEM are shown; each symbol represents an individual mouse.  *** p < 
0.001, **** p < 0.0001; paired student’s t-test.  Data are pooled from two independent 
experiments.  (B) The frequencies of WNV DIII-LR and WNV DIII non-LR binders in swIg 
CD80+CCR6+ MBCs were quantified by flow cytometry.  A representative plot of DIII-
specific MBCs is shown on the left and quantified on the right.  Mean values ± SEM are 
shown; each symbol represents an individual mouse.  *** p < 0.001, **** p < 0.0001; paired 
student’s t-test.  Data are pooled from two independent experiments. (C) Ratios of WNV DIII 
non-LR to WNV DIII LR-specific cells were quantified for GC B cells and MBCs using 
values in (A) and (B).  Mean values ± SEM are shown. *p < 0.05, ** p < 0.01, *** p < 0.001, 
**** p < 0.0001; paired student’s t-test.  (D) The frequency of CD38+CCR6+ expressing MBC 
precursor cells within WNV DIII-LR and WNV DIII non-LR specific GC B cells 




with a representative CD38+CCR6+ gate shown for DIII-LR cells.  Mean values ± SEM are 
shown; each symbol represents an individual mouse.  Data are pooled from two independent 






Figure 2.7 Isolation of mAbs from MBCs and LLPCs.   
 (A) Gating strategy for WNV DIII-specific LLPCs.  LLPCs were first assessed for surface B 
cell receptor expression by analyzing surface kappa expression.  LLPCs in the bone marrow 
were enriched for CD138 expression followed by WNV WT DIII staining with two different 
tetramers. (B) Wild-type mice were immunized with inactivated WNV vaccine, and DIII-
specific MBCs and LLPCs were sorted at least 8 weeks after vaccination. Gating strategy for 
CD19+GL7- WNV DIII-specific MBCs. Splenocytes were depleted of CD3, CD4, CD8, 
CD11b, Ter119, IgM and IgG prior to sorting. (C) Reverse orientation ELISA of a subset of 
DIII-specific mAbs to measure monovalent affinities. ELISA plates were coated with a fixed 
concentration of mAbs and incubated with increasing concentrations of WNV WT DIII.  Mean 
values ± SEM are shown. (D) Example binding curves for representative MBC and LLPC 
mAbs (left, middle) generated by biolayer interferometry with increasing concentrations of 
WNV WT DIII. Binding curves were fit to a 1:1 binding model using ForteBio’s analysis 
software.  The panel below each binding curves shows steady-state analysis results (KD, 
equilibrium), plotted as the binding response (nm) versus concentration of DIII, also shows 
binding saturation.  A Scatchard plot, shown as an insert in the steady-state analysis panels, 
suggests single binding affinity.  The binding association and dissociation constants were 







Figure 2.8 MBCs have lower avidity for their antigens than do LLPCs.  
(A) Monoclonal Abs from WNV-immune mice were isolated from MBCs and LLPCs, and 
WNV DIII reactivity was confirmed by ELISA.  MAb binding curves for WNV WT DIII were 
performed using ELISA. Mean ± SEM are shown. *p < 0.05; 2-way ANOVA. (B) Binding 
affinity (KD, kinetic) to WNV WT DIII for a subset of mAbs was determined by biolayer 
interferometry.  Mean ± SEM are shown; each symbol represents one mAbs. n.s. indicates p > 
0.05; Mann-Whitney test. (C) MAb binding curves for WNV subviral particles (SVPs) were 







Figure 2.9 Deletion of AID during GC reactions does not impair class switching or 
differentiation of MBCs and LLPCs.   
(A) Frequencies of isotype switched (IgM-IgD-) GC B cells (CD19+GL7+) 7 and 14 days after 




cytometry. Mean values ± SEM are shown. Each symbol represents one mouse. Data are 
pooled from two independent experiments. (B) WT mice were immunized with inactivated 
WNV vaccine. WNV DIII+ GC B cells (CD19+GL7+IgD-) were sorted at different time points 
and IgH repertoire analysis was performed by MiSeq. The total number of replacement 
mutations for IgH is shown for each week. (C) WT mice were immunized with inactivated 
WNV vaccine, and the number of DIII-specific bone marrow plasma cells were enumerated by 
ELISPOT at different time points. Representative wells are shown on the left and quantified 
on the right. Mean values ± SEM are shown. Each symbol represents one mouse. Data are 
pooled from two independent experiments. (D) Schematic of experiments to test for Cre 
toxicity. Sera were collected 28 days after vaccination and probed for anti-WNV WT DIII and 
E protein IgG antibodies.  Mean values ± SEM are shown. (E) WNV DIII-specific LLPC 
numbers after WNV vaccination and AID deletion were enumerated by ELISPOT. Mean 
values ± SEM are shown. Each symbol represents one mouse. Data are pooled from two 
independent experiments. (F) Serum from mice after WNV vaccination and AID deletion was 
collected 8 weeks post-immunization, and IgM antibodies were probed for WNV E reactivity 
by ELISA. Mean values ± SEM are shown. Data are pooled from two independent 







Figure 2.10 Absolute affinity thresholds do not segregate MBCs from LLPCs in vivo. 
 (A) Experimental setup to temporally ablate AID during ongoing GC reactions. (B) 
Frequencies of WNV DIII-LR and WNV DIII non-LR specific MBCs were quantified by flow 
cytometry for each AID genotype and deletion group. Mean values ± SEM are shown; each 
symbol represents an individual mouse.  Data are pooled from two independent experiments. 
(C) Serum IgG endpoint titers for WNV WT and WNV KT DIII were calculated by ELISA. 
Mean values ± SEM are shown. Each symbol represents an individual mouse.  Data are pooled 
from two independent experiments. **p < 0.01 and ***p < 0.001; matched 2-way ANOVA.  
(D) Serum from week 1 AID deletion was assessed for WNV SVP binding by ELISA.  Mean 







Figure 2.11 WNV DIII-LR and WNV DIII non-LR naïve and precursor cells are not 
selected from distinct B cell subsets.   




Frequencies of antigen-specific cells in the follicular (FoB) and marginal zone (MZ) B cell 
compartments were enumerated by flow cytometry. A representative flow cytometry plot is 
shown on the left and quantified on the right.  Mean values ± SEM are shown. (B) The 
frequency is shown of V, D, and J immunoglobulin heavy chain gene usage (top) or light chain 
V and J gene usage (bottom) from mAbs derived from MBCs and LLPCs. (C) Frequencies of 
WNV DIII-LR and WNV DIII non-LR-specific cells in Hardy Fractions E (Fr. E) and F (Fr. F) 
were enumerated by flow cytometry. A representative plot is on the left and quantification is 
shown in the middle.  The IgM geometric mean fluorescence intensities (gMFI) of WNV DIII-
LR and WNV DIII-non LR specific cells in Hardy Fractions E and F are quantified on the 
right.  Mean values ± SEM are shown. *p < 0.05; matched 2-way ANOVA.  (D) The number 
of silent and total mutations in the heavy and light chains of the isolated panels of mAbs are 
plotted. Mean ± SEM are shown; each symbol represents one mAb.  *p < 0.05; Mann-Whitney 
test.  (E) WT mice were immunized with inactivated WNV vaccine. WNV DIII+ MBCs 
(CD19+GL7-IgD-IgM-CD80+CCR6+) and WNV DIII+ bone marrow PCs (CD138hiIgM-) were 
sorted at different time points and IgH repertoire analysis was performed by MiSeq. The total 
number of non-silent mutations for IgH is shown for each week.  Mean ± SEM are shown.  







Figure 2.12 Germline affinities of MBC-derived antibodies are lower than those from 
LLPCs.  
(A) MAbs isolated in Figure 4 were reverted to their germline sequences, and binding curves 
against monomeric WNV WT DIII and SVPs were measured by ELISA. Mean values ± SEM 
are shown. ***p < 0.001 and ****p < 0.0001; 2-way ANOVA. (B) The total number of 
replacement mutations in the heavy and light chains of the isolated panels of mAbs are plotted. 
Mean ± SEM are shown; each symbol represents one mAb. (C, D) ELISA binding curves for 
monomeric WNV WT DIII (C) and WNV SVPs (D) are compared for germline-reverted and 
somatically-mutated mAbs from MBCs and LLPCs. Mean ± SEM are shown. Mean ± SEM 







Figure 2.13 Single cell RNA sequencing and lineage tracing validation.   
(A) Gating strategy to sort mature GC B cells one week after WNV vaccination of wild type 




stage for each cluster. (C) UMAP plot showing expression level of Bcl6. (D) UMAP plots 
showing expression of light zone (Cd86) and dark zone (Foxo1 and Cxcr4) genes. (E) Jchain 
expression in GC B cells was confirmed by crossing Jchain to LSL-TdTomato mice and 
administering tamoxifen for two weeks. TdTomato expression was quantified for B cells 
(CD19+ in the spleen or B220+ in the bone marrow), plasma cells (PC, CD138+), non-B cells 
(B220-CD138- in bone marrow, CD19-GL7-CD138- in spleen), and GC B cells (CD19+GL7+). 
Mean values ± SEM are shown. (F) Expected results for TdT-Jchain mice if MBCs are 








Figure 2.14 MBCs are continuously selected from GCs.   




vaccination, subjected to single cell RNA-sequencing and analyzed using Seurat. UMAP plot 
is shown of DIII-specific GC B cells with each uniquely colored cluster segregated by 
differential transcriptional profiles. (B) UMAP plots highlighting the gene expression level per 
cell for GC genes Aicda and Jchain.  (C) UMAP plots highlighting the gene expression level 
per cell for MBC genes. (D) UMAP plots highlighting the gene expression level for GC egress 
(Gpr183 and S1pr1) and retention (S1pr2) genes. (E) Schematic representation of GC lineage 
tracing experiment.  (F) A representative histogram for TdTomato expression in polyclonal 
MBC precursors (CD19+GL7+IgD-IgM-CD38+EfnB1+) is shown (left). The frequency of 
TdTomato expression in the DIII+ and polyclonal MBC precursor, DIII+ GC B cells 
(CD19+GL7+IgD-CD38-EfnB1+) and DIII+ swIg MBC populations is quantified by flow 







MBC Clone Reactivity VH DH JH VK JK 
81D5 DIII-LR IGHV1-76 IGHD1-3 IGHJ4 IGKV6-25 IGKJ5 
82C7 DIII-LR IGHV1-55 IGHD2-3 IGHJ4 IGKV6-25 IGKJ2 
84F8 DIII-LR IGHV1-85 IGHD2-3 IGHJ4 IGKV3-4 IGKJ1 
87C8 DIII-LR IGHV1-55 IGHD2-3 IGHJ2 IGKV6-25 IGKJ1 
8A2 DIII-LR IGHV1-72 IGHD2-4 IGHJ3 IGKV6-17 IGKJ2 
9A10 DIII-LR IGHV1-55 IGHD1-1 IGHJ2 IGKV6-25 IGKJ5 
9B2 DIII-LR IGHV1-55 IGHD1-1 IGHJ3 IGKV6-25 IGKJ1 
9C4 DIII-LR IGHV1-39 IGHD2-12 IGHJ4 IGKV6-25 IGKJ1 
9E12 DIII-LR IGHV1-55 IGHD3-3 IGHJ2 IGKV6-25 IGKJ5 
9F7 DIII-LR IGHV1-85 IGHD1-1 IGHJ1 IGKV6-25 IGKJ5 
2F2 DIII non-LR IGHV1-39 IGHD2-12 IGHJ4 IGKV1-135 IGKJ1 
4C1 DIII non-LR IGHV1-71 IGHD2-1 IGHJ3 IGKV4-55 IGKJ5 
83G4 DIII non-LR IGHV6-3 IGHD1-1 IGHJ2 IGKV4-79 IGKJ5 
8C5 DIII non-LR IGHV5-4 IGHD2-2 IGHJ3 IGKV8-27 IGKJ2 
8D3 DIII non-LR IGHV1-64 IGHD2-13 IGHJ3 IGKV4-55 IGKJ4 
8G3 DIII non-LR IGHV1-22 IGHD3-2 IGHJ3 IGKV6-17 IGKJ1 
       
LLPC Clone Reactivity VH DH JH VK JK 
221A2 DIII-LR IGHV1-55 IGHD2-1 IGHJ4 IGKV6-25 IGKJ5 
221A6 DIII-LR IGHV1-9 IGHD2-1 IGHJ2 IGKV6-25 IGKJ5 
725A4 DIII-LR IGHV1-55 IGHD2-1 IGHJ2 IGKV6-25 IGKJ5 
725A9 DIII-LR IGHV1-55 IGHD2-1 IGHJ2 IGKV6-25 IGKJ5 
725B11 DIII-LR IGHV1-76 IGHD4-1 IGHJ2 IGKV6-25 IGKJ4 
725B1 DIII-LR IGHV1-76 IGHD6-3 IGHJ4 IGKV6-25 IGKJ5 
725C5 DIII-LR IGHV5-9 IGHD1-1 IGHJ2 IGKV6-25 IGKJ1 
725D3 DIII-LR IGHV1-76 IGHD1-1 IGHJ2 IGKV6-25 IGKJ2 
725D9 DIII-LR IGHV1-52 IGHD2-3 IGHJ3 IGKV4-55 IGKJ5 
725E2 DIII-LR IGHV1-55 IGHD1-1 IGHJ2 IGKV6-25 IGKJ5 
725F10 DIII-LR IGHV1-9 IGHD2-2 IGHJ2 IGKV6-25 IGKJ2 
725G11 DIII-LR IGHV1-85 IGHD1-1 IGHJ2 IGKV6-25 IGKJ5 
725G6 DIII-LR IGHV1-76 IGHD4-1 IGHJ2 IGKV6-17 IGKJ5 
725G7 DIII-LR IGHV1-55 IGHD1-1 IGHJ2 IGKV6-25 IGKJ1 
725H11 DIII-LR IGHV1-61 IGHD2-2 IGHJ4 IGKV3-10 IGKJ1 
725H5 DIII-LR IGHV1-85 IGHD1-1 IGHJ3 IGKV6-25 IGKJ5 
626A3 DIII-LR IGHV1-72 IGHD1-3 IGHJ3 IGKV6-25 IGKJ4 
626A7 DIII-LR IGHV1-55 IGHD1-1 IGHJ2 IGKV6-25 IGKJ5 
725B4 DIII non-LR IGHV1-82 IGHD2-1 IGHJ2 IGKV9-124 IGKJ4 
626C1 DIII non-LR IGHV1-26 IGHD2-4 IGHJ2 IGKV3-2 IGKJ1 
 
Table 2.1.  V, D, and J gene usages for mAbs derived from MBCs and LLPCs.   
MAbs isolated in Figure 2.8 were subject to V(D)J gene usage analysis for both the heavy (H) 







Chapter 3:  
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Long-term B cell mediated immunity is provided by long-lived plasma cells (LLPCs) and 
memory B cells (MBCs).  LLPCs secrete antibodies to provide sterilizing immunity whereas 
MBCs provide protection only after reactivation and differentiation into plasma cells.  LLPCs 
and MBCs primarily differentiate from germinal center (GC) B cells.  Thus, these three B cell 
compartments are critical for generating durable immunity.  Members of the broad complex, 
tram track, bric-a-brac and zinc finger (BTB-ZF) family of transcription factors include BCL-6, 
ZBTB20, and ZBTB32.    These transcription factors regulate key aspects of B cell responses.  
BCL-6 is essential for GC formation.  ZBTB20 regulates the durability of LLPC responses in an 
adjuvant dependent manner.  ZBTB32 is important for restricting the durability of memory B 
cell recall responses.  ZBTB38 is another member of the BTB-ZF family, whose functional 
importance in hematopoiesis and B cells has not been characterized.  Here, we demonstrate that 
ZBTB38 is dispensable for the development of many mature hematopoietic lineages as well as 





Humoral immunity to an infection or vaccination is mediated by long-lived plasma cells 
(LLPCs) and memory B cells (MBCs), which have distinct antigen specificities and therefore 
mediate different aspects of immunity 1.  LLPCs constitutively secrete antibodies, and are 
important for providing protection against re-infection by the same pathogen.  Memory B cells, 
on the other hand, can only provide protection after re-activation by a cognate antigen by rapidly 
differentiating into plasma cells.  Recent studies have identified the broad complex, tram track, 
bric-a-brac and zinc finger (BTB-ZF) family of transcription factors as key regulators in B cell 
development.  BTB-ZF family members are involved in many cellular processes by binding 
DNA through its variable number of C-terminal zinc finger domains and recruiting SMRT co-
repressors and histone deacetylases to its N-terminal BTB/POZ domain 2, 3, 4, 5, 6.  Notable 
members include BCL-6, ZBTB20, and ZBTB32, where each member regulates distinct aspects 
of B cell mediated immunity.  BCL-6 is important for germinal center (GC) formation 7, 
ZBTB20 promotes durable immunity in an adjuvant dependent manner 8, 9, and ZBTB32 restricts 
memory B cell recall responses 10, 11.  Thus, understanding the role of additional BTB-POZ 
members in regulating B cell responses may provide further insight into how the durability of B 
cell memory responses are established.  
ZBTB38, also known as CIBZ (CtBP-interacting BTB zinc finger protein) is another 
member of the BTB-ZF family, and can function either as a transcriptional repressor or activator 
12.  ZBTB38 transcriptional regulation occurs by binding primarily to sequence-specific, 
methylated CpG sequences and recruiting transcriptional repressors or activators 13, 14, 15.  
ZBTB38 has been shown to repress overall transcription by inhibiting expression of MCM10, a 




regulate cell cycle progression, cellular differentiation, and apoptosis 17, 18, 19, 20, 21.  Given the 
ability of ZBTB38 to regulate cell cycle progression and anti-apoptosis, we hypothesized that 
ZBTB38 is important for regulating GC reactions, which require a balance between proliferation 
and apoptosis.  Quantitative real-time PCR of different B cell subsets revealed elevated 
expression of ZBTB38 in GC B cells and plasma cells compared to naïve B cells.  Here, we 
demonstrate that ZBTB38 deficiency does not impair primary or secondary B cell responses to a 





Generation and validation of ZBTB38 floxed mice. 
To assess the role of ZBTB38 in vivo, we generated Zbtb38 floxed mice by targeting 
exon 3 using CRISPR technology (Figure 3.1A).  NdeI and EcoRI restriction sites were 
introduced near the 3’ LoxP and 5’ LoxP sites to screen for successful integration of the plasmid.  
Correct targeting of exon 3 was confirmed by PCR and restriction enzyme digestions, where 
genomic DNA sequences flanking exon 3 was amplified followed by single and double 
restriction enzyme digests with NdeI and EcoRI (Figure 3.1B).  Wild-type, targeted, and deleted 
Zbtb38 mice can be differentiated using a set of three primers that flank the 5’ and 3’ LoxP 
sequences (Figure 3.1C).  To confirm deletion of Zbtb38 exon 3 at the genomic level, Zbtb38 f/f 
mice were crossed to mice expressing CMV-Cre to obtain germline ZBTB38 deletion.  Genomic 
DNA from Zbtb38 f/f x CMV-Cre was amplified where deletion was confirmed by a 4 kb 
reduction in PCR size (Figure 3.1D).  ZBTB38 germline deletion did not result in gross 
developmental abnormalities. No differences in the number or size of ZBTB38 deficient and 
wild-type mice were observed (data not shown).    
 
ZBTB38 deficiency does alter the development of hematopoietic cells 
ZBTB38 gene expression in multiple cell types was analyzed using available RNA-
sequencing data assembled by the ImmGen Consortium.  A subset of cell types expressing 
DESeq2 normalized ZBTB38 levels greater than 800 are shown in Figure 3.2A.  Given the high 
expression of ZBTB38 in hematopoietic stem cells (HSCs), and downstream lineages such as B 
and T cells, we crossed Zbtb38 f/f mice to VavCre mice (Zbtb38 f/f x VavCre, ZBTB38 KO), 




We first assessed if ZBTB38 deficiency alters the development of hematopoietic lineages 
under physiological conditions by quantifying the frequencies of different cell populations by 
flow cytometry.  We first focused on hematopoietic stem cells (HSCs, cKit+Sca1+Flk2-CD27+) 
and progenitors with varying degrees of lineage commitment in the bone marrow 22.  HSCs 
differentiate into multipotent progenitors (MPPs, cKit+Sca1+Flk2+CD27+) that can give rise to 
both the myeloid and lymphoid lineages.  MPPs can then differentiate into common myeloid 
progenitors (CMPs, cKit+Sca1-Flk2+FcgR-) or common lymphoid progenitors (CLPs, cKit-
/loSca1-CD27+FcgR-Flk2+IL7Ra+)23, 24.  CLPs give rise to B, T, natural killer (NK), and innate 
like cells (ILCs).  CMPs give rise to basophils, eosinophils, mast cells, dendritic cells as well as 
granulocyte monocyte progenitors (GMPs, cKit+Sca1-Flk2-FcgR+) 24.  GMPs can then give rise to 
neutrophils and monocytes.  We identified no statistically significant differences in the 
frequencies of these progenitor populations between ZBTB38 WT and KO mice (Figure 3.2B).  
Although ZBTB38 was not required for the maintenance and differentiation of hematopoietic 
progenitors, it does not preclude the possibility that ZBTB38 is required for the development of 
mature lineages.   
To assess if mature hematopoietic lineages require ZBTB38 for their development, we 
analyzed the frequencies of different peripheral blood mononuclear cell (PBMCs) populations.  
We observed no differences between ZBTB38 WT and KO mice in the frequencies of B cells 
(B220+), NK cells (NK1.1+), T (CD4+ or CD8+ B220-NK1.1-CD11b-), monocytes 
(CD11b+Ly6ChiLy6G-), or neutrophils (CD11b+Ly6C+Ly6G+) (Figure 3.2C).  Thus, ZBTB38 is 
not required for the development or maintenance of these hematopoietic lineages.  We next 





ZBTB38 is highly expressed in germinal center B cells.  
Further analysis of ImmGen’s RNA-sequencing data identified highest expression of 
ZBTB38 in splenic, short-lived plasma cells (SLPCs, data not shown).  However, ImmGen’s 
microarray data identified highest expression of ZBTB38 in GC B cells (data not shown).  Thus, 
we decided to confirm ZBTB38 expression in GC B cells and SLPCs by quantitative real-time 
PCR.  Wild-type mice were immunized with alhydrogel-adjuvanted 4-hydroxy-3-nitrophenyl-
acetyl (NP) conjugated to ovalbumin (OVA) and naïve B cells (CD19+CD138-), NP-specific 
dark (CXCR4+) and light zone (CD86+) GC B cells (CD19+GL7+IgD-), and NP-specific SLPCs 
(CD138+) were sorted 11 days after immunization.  RNA was extracted from sorted cells and 
quantitative real-time PCR performed to quantify ZBTB38 transcript levels.   GC B cells and 
SLPCs contained 9- or 3-fold, respectively, higher expression of ZBTB38 compared to naïve B 
cells (Figure 3.3).   No differences in ZBTB38 expression were observed between light and dark 
zone GC B cells.  These data suggest that ZBTB38 might be functionally involved in primary 
antibody responses.   
 
ZBTB38 deficiency does not impair primary B cell responses. 
To determine if ZBTB38 has a functional role in primary B cell responses, we first 
examined GC reactions.  We immunized ZBTB38 WT and KO mice with NP-OVA and 
quantified the frequency of NP-specific GC B cells 2 weeks later, which corresponds with peak 
GC reactions 25.  We observed no differences in the frequencies of NP-specific GC B cells 
between ZBTB38 WT and KO mice (Figure 3.4A), indicating that ZBTB38 is not required for 
the expansion of NP-specific GC B cells.  We next wondered if ZBTB38 is important for plasma 




expression, given the transcriptional similarity between SLPCs and LLPCs 26, it is possible that 
ZBTB38 may also potentially regulate LLPC differentiation or function.  Additionally, although 
ZBTB38 deficiency does not alter antigen specific GC B cell expansion, it may impair plasma 
cell differentiation or antibody secretion.   
To assess both SLPC and LLPC function, ZBTB38 WT and KO mice were immunized 
with alhydrogel-adjuvanted NP-OVA and NP-specific serum antibodies were quantified over 
time by ELISA.  The levels of NP-specific antibodies, captured using NP16, were similar 
between ZBTB38 WT and KO mice at all time points measured (Figure 3.4B).  To specifically 
quantify the level of high affinity antibodies in the serum by ELISA, low density antigen (NP4) 
was used to probe for antibody binding.  Low density NP (NP4) is used to capture antibodies 
with slow off-rates, which is correlated with antigen high affinity.  This contrasts with high 
density NP (NP16), which can capture antibodies with slower off rates due to decreased distance 
between NP molecules.  Unlike the total number of NP-specific antibodies over time, which 
plateaued two weeks after immunization, the number of high affinity antibodies increased 
steadily over time and plateaued four weeks after immunization (Figure 3.4C).  No difference in 
the quantity of high affinity antibodies was observed between ZBTB38 WT and KO mice 
(Figure 3.4C).  Furthermore, the extent of affinity maturation, quantified as the ratio of NP4 to 
NP16 endpoint titers, was similar between ZBTB38 WT and KO mice (Figure 3.4D).  Possible 
explanations for the similar serum antibody levels in ZBTB38 WT and KO mice include similar 
frequencies for antigen-specific LLPCs or compensatory increased antibody secretion from 
fewer LLPCs.   
To differentiate between these two possibilities, the frequency of NP-specific LLPCs was 




ZBTB38 WT and KO mice.  The frequency of NP-specific LLPCs was similar between ZBTB38 
WT and KO mice, suggestion that ZBTB38 does not have a functional role in plasma cells.  Our 
data thus far demonstrate that ZBTB38 is not required for either GC expansion or plasma cell 
differentiation and function.  We next speculated that perhaps the high expression of ZBTB38 in 
GC B cells is important for initiating a transcriptional program required for subsequent memory 
B cell differentiation or function.   
 
ZBTB38 deficiency does not alter recall responses. 
To determine if ZBTB38 expression is required for MBC differentiation, the frequency of 
NP-specific memory B cells (CD19+GL7-IgM-IgD-CD80+CCR6+) was quantified in ZBTB38 
WT and KO mice 8 weeks after immunization with alhydrogel-adjuvanted NP-OVA.  No 
difference in the frequency of NP-specific MBCs was observed (Figure 3.5A).  Thus, ZBTB38 
is not required for the differentiation of memory B cells, but may still be required for MBC 
reactivation.  To determine if ZBTB38 deficiency alters recall responses, splenocytes from 
ZBTB38 WT and KO mice were adoptively transferred into allotype-distinct naïve IgHa hosts 
and mice challenged with soluble NP-OVA 24 hours later.  Donor IgHb NP-specific antibodies 
originating from ZBTB38 WT and KO mice were tracked over time.  NP-specific antibody titers 
were not altered with ZBTB38 deficiency (Figure 3.5B).  Thus, ZBTB38 is also dispensable for 





BTB-ZF family members such as BCL-6, ZBTB32, and ZBTB20, have demonstrated 
critical roles in regulating different aspects of B cell responses.  Our data demonstrate that 
ZBTB38, another member of the BTB-POZ family, is dispensable for maintaining homeostasis 
of lymphoid and myeloid hematopoietic lineages.  In addition, ZBTB38 is also dispensable for 
both primary and recall B cell responses to a hapten antigen.  While hapten immunogens are 
useful in studying B cell responses, they are not representative of B cell responses to protein 
antigens.  Thus, future studies should asses the role of ZBTB38 in regulating B cell responses to 
protein antigens or pathogens.  Not only is ZBTB38 highly expressed in different hematopoietic 
lineages, it is also highly expressed in neurons.  This suggests that ZBTB38 may have a role in 
neuronal function.   
Various models of ZBTB38 deletion or knockdown have resulted in impaired cellular 
processes in neuronal injuries or tumors.  For instance, increasing ZBTB38 expression reduces 
apoptosis and promotes autophagy in a spinal cord injury model, and results in increased 
neuronal repair  21, 27, 28.   In contrast, ZBTB38 expression has been shown to promote 
proliferation and differentiation of a neuroblastoma cell line 29.  These differences in the 
functional roles of ZBTB38 may be attributed varying sensitivity of different neurons to 
oxidative stress 30.  ZBTB38, along with USP9X, a deubiquitinase, is required to limit basal 
reactive oxidative species (ROS) levels and the response to oxidative stress 31.  Give the high 
levels of ZBTB38 in neurons, perhaps ZBTB38 is involved with balancing neuronal death with 
recovery after various challenges.  To further understand the functional importance of ZBTB38 




different neuronal function assessed.  Neuronal insult, such as injury, stroke, or cancer may be 
necessary to identify processes regulated by ZBTB38.   
Genome-wide association studies in humans have identified single nucleotide 
polymorphisms (SNPs) in ZBTB38 that are associated with shorter stature in Chinese 
populations but taller stature in Korean populations 32, 33, 34, 35.  However, when Zbtb38 f/f mice 
were crossed to CMV-Cre expressing mice, germline deletion of ZBTB38 did not result in 
observable differences in the length or weight of the mice (data not shown).  Further 
characterization of how SNPs influence ZBTB38 function, and identifying the location of SNPs, 
may provide further explanation of why certain polymorphisms are associated with increased 
height while other SNPs are associated with decreased height.    
Together, our data indicate that ZBTB38 is likely not important for the development or 
steady-state maintenance of hematopoietic lineages.  In addition, primary and recall B cell 
responses to a hapten antigen do not require ZBTB38.  Of course, it remains possible that defects 
exist in rare subsets of lineages that we did not analyze. Future studies focused on other cell 






Mice.   
All animal procedures used on mice were approved by the Animal Care and Use Committees at 
Washington University and at the University of Arizona.  All mice were housed and bred in 
pathogen-free facilities.  C57BL6/N mice were obtained from the National Cancer Institute.  
B6.Cg-IghaThy1aGpi1a (IgHa) mice were obtained from Charles River Laboratories.  ZBTB38f 
embryonic stem cells were generated at the Genome Engineering and iPSC center at Washington 
University School of Medicine and injected into B6 albino (Jackson Laboratory, stock no. 
000058) mice by the Transgenic Knockout Microinjection Core facility at Washington 
University in St. Louis.  ZBTB38 f/f mice were crossed to CMV-Cre (Jackson Laboratory, stock 
no.  006054) or VavCre (Jackson Laboratory, stock no.  008610) and maintained as ZBTB38 f/f 
or ZBTB38 x CMV- or Vav-Cre where littermates were used as controls.  The following primers 
were used for genotyping the Zbtb38 allele: 5’LoxP forward 5’- 
TCTGAGTTCAAGGCCAGCTT-3’, 5’LoxP reverse 5’- TCTCCAAGCAGAAAGGGTGT-3’, 
and 3’LoxP reverse 5’- GGGTCGTTAGAGGATTCAGC-3’.   
 
Immunizations.   
Mice were immunized intraperitoneally with 100 μg NP-OVA (Biosearch), adjuvanted with 
Alhydrogel (Invivogen). NP-APC used for staining was made by conjugating allophycocyanin 
(Sigma-Aldrich) with 4-hydroxy-3-nitrophenylacetyl-O-succinimide ester (Biosearch 






RNA extraction, cDNA synthesis, and qRT-PCR.   
Total RNA was extracted with TRIzol (Life technologies) and cDNA synthesized using 
Superscript III Reverse transcription kit with random hexamers (Life Technologies) according to 
manufacturer’s instructions.  qRT-PCR was performed using SYBR Green PCR master mix 
(Applied Biosystems) on a Prism 7000 Sequence Detection System (Applied Biosystems).  The 
primers used for Zbtb38 are: forward 5’- AGAACCAAGGATTTCCGAGTG-3’ and reverse 5’-
GATGGAGAGTACTGTGTCACTG-3’.  Zbtb38 transript levels were normalized to 18S 
ribosomal RNA, forward 5’-CGGCTACCACATCCAAGGAA-3’ and reverse 5’-
GCTGGAATTACCGCGGCT-3’ 36.   
 
ELISA.   
ELISA plates (9018, Corning) were coated overnight at 4°C in 0.1 M sodium bicarbonate buffer, 
pH 9.5 containing 5 ug/mL of NP16- or NP4-BSA (Bioresearch Technologies). All other 
incubation steps were performed at room temperature for 1 hour.  Wash steps were performed 
between each step using PBS + 0.05% Tween-20.  Plates were blocked with PBS + 2% BSA 
followed by serial dilutions of serum. Serum was probed with 0.1 ug/mL of biotinylated anti-
mouse IgG (715-065-151, Jackson ImmunoResearch Laboratories) and then detected with 
streptavidin conjugated horseradish peroxidase (554066, BD biosciences).  Plates were 
developed using TMB (Dako, S1599) and neutralized with 2N H2SO4.  Optical density (OD) 
values were measured at 450 nm. Serum endpoint titer was defined as the inverse dilution factor 
that is three standard deviations above background using one-phase decay measurements and 





Adoptive transfer for recall responses.   
Splenocytes from NP-immunized ZBTB38f/f or ZBTB38f/f x VavCre mice were isolated and 
processed into single cell suspension.  erythrocytes lysed using an ammonium chloride-
potassium solution, and lymphocytes isolated by using a Hisopaque-1119 (Sigma-Aldrich) 
density gradient.  Cells were washed twice prior to transfer.  10% of cells were retained for 
cellular analysis whereas the remaining 90% of cells were transferred into one non-irradiated 
IgHa recipient mice by intravenous injection.  A recall response was elicited by intravenously 
challenging mice with soluble NP-OVA 24 hours later.   
 
Flow cytometry.   
Single cell suspensions were prepared from bone marrow or spleen, erythrocytes lysed using an 
ammonium chloride-potassium solution, and lymphocytes isolated by using a Hisopaque-1119 
(Sigma-Aldrich) density gradient.  Cells were resuspended in PBS with 5% adult bovine serum 
and 2 mM EDTA prior to staining with antibodies and NP-APC.  The following antibodies were 
purchased from Biolegend: 6D5 (CD19)-Alexa Fluor 700; GL7-FITC; 281-2 (CD138)-PE; 
RMM-1 (IgM)-APC; 11-26c.2a (IgD)-PerCP-Cy5.5 or -Brilliant Violet 605; 16-10A1 (CD80)-
PE; RA3-6B2 (B220)-FITC, -Pacific Blue, or APC-Cy7; PO3 (CD86)-FITC; PK136 (NK-1.1)-
PerCP-Cy5.5; M1/70 (CD11b)-Pacific Blue; HK1.4 (Ly-6C)-Brilliant Violet 510; 1A8 (Ly-6G)-
Brilliant Violet 605; A7R34 (IL-7R)-Brilliant Violet 421; and E13-16.7 (Ly-6A/E)-PE.  The 
following antibodes were purchased from eBioscience: 11/41 (IgM)-PerCP-e710; 11-26c (IgD)-
FITC; 2B11 (CXCR4)-PerCP-e710; 2B8 (c-Kit)-PE-Cy7; and LG.7F9 (CD27)-APC.  The 
following antibodies were purchased from BD Pharmingen: 53-6.7 (CD8a)-PE; RM4-5 (CD4)-




Cells were stained on ice for 20 minutes.  Germinal center B cells were enriched by staining cells 
with GL7-PE followed with anti-PE magnetic beads (0.5 uL/107 cells, Miltenyi Biotec).  Positive 
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Figure 3.1 Zbtb38 targeting strategy and confirmation of deletion.   
(A) Targeting construct of Zbtb38 exon 3.  NdeI and EcoRI restriction sites were introduced to 
allow for screening of plasmid integration.  (B) PCR showing that exon 3 is correctly targeted.  
Lane 1 is the undigested PCR product, lane 2 is a NdeI digest (expected band sizes of 5.8 kb 
and 445 bp), lane 3 is a EcoRI digest (expected band sizes of 2.6 kb, 2 kb, and 1.6 kb), and 
lane 4 is a NdeI and EcoRI double digest (expected band sizes of 445 bp, 2.1 kb, 2 kb, and 1.6 
kb).  (C) PCR showing that Zbtb38 can be deleted upon Cre activity.  Primers used are the 
same ones used to amplify the genomic DNA in (B). (D) Genotyping strategy to identify if a 







Figure 3.2 ZBTB38 deficiency does not alter the development of hematopoietic cells.   
(A) ZBTB38 expression values in select cell subsets were extracted from ImmGen’s RNA-seq 
SKYLINE and grouped based on cell type.  Cell types shown have a ZBTB38 expression 
value, normalized by DESeq2, of 800 or greater.   (B) The frequencies of hematopoietic stem 
cells (HSCs, cKit+Sca1+Flk2-CD27+), multi-potent progenitors (MPPs, 
cKit+Sca1+Flk2+CD27+), common myeloid progenitors (CMPs, cKit+Sca1-Flk2+FcgR-), 
granulocyte monocyte progenitors (GMPs, cKit+Sca1-Flk2-FcgR+), and common lymphoid 
progenitors (CLPs, cKit-/loSca1-CD27+FcgR-Flk2+IL7Ra+) in the bone marrow from ZBTB38 
WT and KO mice were quantified by flow cytometry.  Mean ± SEM are shown; each symbol 
represents an individual mouse. Statistical significance was determined by unpaired student’s 
2-tailed t-test; n.s. indicates no significance (p > 0.05).  Data shown are from one experiment.  
(C) The frequencies of B cells (B220+), natural killer (NK, NK1.1+) cells, CD4+ and CD8+ T 
cells (B220-CD11b-NK.1-), monocytes (CD11b+Ly6ChiLy6G-), and neutrophils 
(CD11b+Ly6C+Ly6G+) of peripheral blood mononuclear cells (PBMCs) from ZBTB38 WT 
and KO mice were quantified by flow cytometry.  Mean ± SEM are shown; each symbol 
represents an individual mouse.  Statistical significance was determined by unpaired student’s 







Figure 3.3 ZBTB38 expression level in select B cell subsets.   
Naïve B cells, antigen-specific dark (DZ, CXCR4+) and light (LZ, CD86+) zone germinal 
center B cells (GCBC, CD19+GL7+IgD-), and splenic plasma cells (SpPC, CD138+) were 
sorted and Zbtb38 RNA levels quantified by quantitative real time PCR.  Zbtb38 expression 
level was first normalized to 18S expression level followed by normalization to naïve B cells.  
Mean ± SEM are shown; each symbol represents an individual mouse.  Data shown are from 







Figure 3.4 ZBTB38 deficiency does not impair primary B cell responses. 
(A) ZBTB38 WT and KO mice were immunized with NP-OVA and the frequency of NP-
specific germinal center B cells two weeks post immunization was quantified by flow 
cytometry.  Mean ± SEM are shown; each symbol represents an individual mouse.  Statistical 
significance was calculated by unpaired student’s two-tailed t-test; n.s. = not significant (p > 
0.05).   (B, C) ZBTB38 WT and KO mice were immunized with NP-OVA and total serum 
antibody titers (B) and high affinity serum antibody titers (C) to NP were quantified by ELISA.  
Endpoint titers are calculated as the reciprocal serum dilution that was three standard 
deviations above background. Mean ± SEM are shown; each symbol represents an individual 
mouse.  Statistical significance was calculated by Mann-Whitney test; n.s. = not significant (p 
> 0.05).  (D) Affinity maturation of the antibodies was calculated as the ratio of endpoint titers 
to NP4 : NP16 and plotted at each time point for ZBTB38 WT and ZBTB38 KO mice.  Mean ± 
SEM are shown; each symbol represents an individual mouse.  (E) The frequency of NP-
specific long-lived plasma cells was calculated by flow cytometry.   The long-lived plasma 
cells were analyzed 8 weeks post-NP immunization.  Mean ± SEM are shown; each symbol 
represents an individual mouse.  Statistical significance was calculated by unpaired student’s 







Figure 3.5 Recall responses to NP do not require ZBTB38.   
(A) The frequency of NP-specific memory B cells (CD19+GL7-IgM-IgD-CD80+CCR6+) was 
quantified by flow cytometer in ZBTB38 WT and KO mice 8 weeks after NP-OVA 
immunization.  Mean ± SEM are shown; each symbol represents an individual mouse.  
Statistical significance was calculated by unpaired student’s two-tailed t-test; n.s. = not 
significant (p > 0.05). Data shown is from one experiment.  (B) Splenocytes from ZBTB38 
WT and ZBTB38 KO mice were adoptively transferred into IgHa naïve hosts and challenged 
with soluble NP-OVA one day after transfer.  Donor (IgHb) antibody responses were 
calculated as the endpoint titer against high density NP.  Mean ± SEM are shown; each symbol 
represents an individual mouse.  Statistical significance was calculated by Mann-Whitney test; 












In this study, we characterized the generation and utilization of diverse memory B cells in 
their native environment following heterologous flavivirus challenges, and thus provide an 
etiological explanation for the existence of memory B cells.  A primary flavivirus challenge 
generates flavivirus-specific long-lived plasma cells (LLPCs) but broadly reactive memory B 
cells (MBCs).  These broadly reactive MBCs respond to a secondary heterologous challenge 
without undergoing further affinity maturation.  Therefore, we propose that MBCs have been 
evolutionarily selected for in order to provide anticipatory protection against antigens that have 
evaded neutralization by serum antibodies and heterologous pathogen.  This in turns provides 
more rapid protection against the secondary pathogen compared to a naïve B cell response.  
While our study contributes to a better understanding of how MBCs are generated and utilized, 
future work should clarify whether GC-biased MBCs can even be engaged during recall 
responses and to mechanistically define cues that promote the differentiation of MBCs from GC 
B cells.   
Analysis of MBC subsets in WNV vaccinated mice identified DIII-specificity exclusively 
in the CD80+, plasma cell-biased MBC subset (Figure 2.5A).  Thus, this observation cannot 
definitively exclude the possibility that the lack of GCs after a secondary heterologous challenge 
is due to the absence of GC-biased MBCs.  Preliminary analysis of MBC subsets in WNV 
infected mice identified the existence of both plasma cell-biased and GC-biased MBCs.  Future 
work using WNV infection followed by JEV infection is necessary to more conclusively show 
that MBCs generated after a primary flavivirus infection respond to heterologous infection by 
directly differentiating into plasma cells to provide protection.  Although we utilized DENV and 
ZIKV sequential infections to further support that MBCs do not require further affinity 




distribution of DENV-specificity in different MBC subsets prior to ZIKV infection.  Thus, it is 
unclear if the DENV infection generated GC-biased MBCs that could be potentially engaged 
upon secondary challenge.  Should a primary infection result in the engagement of GC-biased 
MBCs upon a heterologous secondary infection, further studies clarifying signals that promote 
the differentiation of GC-biased versus plasma cell-biased MBCs, as well as their antigen 
specificities, are necessary.  Such signals may originate from the cytokine milieu and/or strength 
of BCR signaling. 
Irrespective of the ability of GC-biased MBCs to be engaged during secondary recall 
responses, it remains to be seen how MBCs respond to a tertiary flavivirus challenge.  Secondary 
flavivirus challenges result in the activation of cross-reactive MBCs, of which a minority binds 
the neutralizing LR epitope.  Thus, how do neutralizing and non-neutralizing antibodies derived 
from cross-reactive MBCs impact tertiary heterologous challenges?  Will ADE of the tertiary 
challenge occur?  Will original antigenic sin occur by further activating cross-reactive MBCs 
that responded to the secondary heterologous challenge, or will a tertiary heterologous challenge 
activate a different subset of cross-reactive MBCs generated after the primary challenge?  To 
address these questions, the MBC and antibody specificities after a tertiary challenge need to be 
assessed.  This is important for better understanding how the breadth of MBCs is utilized upon 
sequential challenges.   
In addition to understanding how MBCs respond to tertiary heterologous challenges, it is 
important to understand how disparate antigens have to be in order to bypass MBC reactivation 
and initiate naïve B cells responses.  Our data indicate that sequential challenges between 
flaviviruses that are approximately 55% and 75% similar at the DIII amino acid sequence level 




Thus, it remains to be seen if flaviviruses that are more disparate can still initiate cross-reactive 
responses.  To address this, future experiments secondary challenges utilizing flaviviruses that 
are more or less disparate than the primary challenge are necessary.  For instance, what is the 
response between a St. Louis Encephalitis Virus (SLEV) primary challenge and a Dengue virus 
(DENV) secondary challenge, where SLEV and DENV share approximately 40% DIII sequence 
identity?   
Thus far, we have focused on the utilization of MBCs upon recall challenge.  However, it 
is still unclear what cues promote the MBC fate.  Two mechanisms for MBC differentiation have 
been proposed.  One is the temporal switch in which GCs go from supporting MBC fate during 
early reactions to supporting LLPC fate during late reactions 1.  The other is the selection of low 
affinity GC B cells into the MBC compartment due to weaker T cell help, and thus elevated 
levels of Bach2 2.  While these two mechanisms are not completely mutually exclusive, 
especially during early GC reactions, it is unclear how GC environments change over time, and 
how that in turn impacts GC B cell selection, affinity maturation, and differentiation.  Here, we 
demonstrate that a continuous, but active, selection of relatively low affinity germinal centers 
into the MBC compartment likely promotes the diversity of MBCs (Figure 2.14F).  The active 
selection conclusion is based on the significant enrichment of MBCs for DIII-nonLR specificity 
compared to their GC B cell precursors (Figure 2.6C).  In addition, DIII-nonLR specific GC B 
cells were enriched for MBC precursor surface markers (Figure 2.6D).  Thus, DIII-nonLR 
specificity can perhaps be used as a surrogate marker for an ultimate MBC fate, and thus aid in 
identifying signals that promote the MBC fate.   
Additionally, it is necessary to have a better understanding of how DIII-nonLR and DIII-




not LLPCs.  One hypothesis is that DIII-nonLR specific cells perhaps have different 
transcriptional or chromatin-accessibility signatures relative to DIII-LR specific cells.  In this 
case, single cell RNA- and ATAC-sequencing over time may provide clues to why DIII-nonLR 
specific cells are predisposed towards the MBC fate.  We would expect that DIII-nonLR specific 
cells have a greater MBC signature than DIII-LR specific cells.  Alternatively, perhaps DIII-
nonLR specific GC B cells are constantly of lower affinity compared to DIII-LR specific GC B 
cells.  Bulk VDJ sequencing of the heavy chain from WNV DIII-LR and -nonLR specific GC B 
cells over time identified a reduced mutational load in DIII-nonLR specific cells (data not 
shown).  However, analysis of DIII-LR and DIII-nonLR MBC-derived mAbs did not reveal 
binding differences to WNV WT DIII.  Thus, it is inconclusive if DIII-nonLR specific GC B 
cells are of consistently lower affinity or not.  To test this, monoclonal antibodies from GC B 
cells over time need to be produced.  Or over time, DIII-specific GC B cells from WNV 
vaccinated Nur77 reporter mice can be analyzed for GFP expression, which corresponds to 
strength of BCR signaling. Yet another hypothesis for why DIII-nonLR specific cells are 
enriched in the MBC compartment is that DIII-LR and -nonLR specific cells are differentially 
sensitive to BCR stimulation.  Analysis of Hardy Fractions E and F revealed a slight reduction in 
surface IgM levels in Fraction E DIII-LR cells compared to DIII-nonLR cells, although this 
reduction was not maintained in the recirculating mature Fraction F population.  Given that 
lower surface IgM levels correlate with anergy, and that anergic B cells can still participate in 
GC reactions 3, perhaps DIII-LR specific cells require a higher activation threshold for 
differentiation.  To test this, calcium flux assays can be performed using different concentrations 
of DIII.  What we would expect is that DIII-LR specific cells would require a higher 




Although our study focuses on flaviviruses infections, it can be applied to different 
infections.  In the context of flaviviruses, we propose that the diversity of MBCs may negatively 
impact the host response towards heterologous challenges due to the increased likelihood of 
generating poorly neutralizing but broadly reactive antibodies, which in turn may promote ADE.  
The inability of MBCs to remodel their specificity towards new antigens by re-initiating GC 
reactions indicates that the primary response is critical for defining secondary responses.  Thus, 
vaccine efforts should focus on two aspects: 1) limit the diversity of MBCs and 2) focus 
responses towards neutralizing epitopes that are type specific.  However, for rapidly mutating 
pathogens such as influenza, a diverse MBC compartment may be beneficial.   
The constantly evolving nature of influenza, especially at the hemagglutinin (HA) head, 
means that neutralizing anti-HA head antibody responses to one influenza strain is unlikely to 
neutralize another strain.  Thus, current vaccine efforts have focused on mounting antibody 
responses against the conserved HA stem region.  Careful analysis of newly generated and pre-
existing MBCs after secondary influenza exposure revealed the inability of stem-reactive MBCs 
to affinity mature 4.  These findings corroborate our findings where MBCs do not undergo 
further affinity maturation after re-activation.  In the context of influenza infections, we 
hypothesize that MBC diversity may be beneficial to the host since it increases the likelihood of 
recognizing variant antigens, especially at the conserved hemagglutinin (HA) stem region.  Thus, 
we propose that influenza vaccine strategies should focus on generating a broadly reactive 
primary MBC pool that has the potential to recognize multiple variants, either at the HA head or 
stem.  Immunogen design, such as hyperglycosylation of the HA head, may aid in focusing the 
MBC response towards stem epitopes by increasing the accessibility of the HA stem during a 




Our findings can also be applied to another problematic pathogen, HIV.  HIV also 
constantly evolves over time where broadly neutralizing antibodies are associated with high 
levels of somatic hypermutation.  Current vaccine strategies focus on guiding the B cell response 
through sequential immunizations with variant antigens or by targeting public clonotypes 6.  
These strategies rely on the re-initiation of GCs by MBCs to further somatically hypermutate 
their BCRs.  However, our data indicate that MBCs are unable to further affinity mature. 
Therefore, sequential activation of MBCs in hopes of re-initiating GCs and further somatically 
hypermutate BCRs to generate broadly neutralizing antibodies (bnAbs) is likely an ineffective 
strategy.  Instead, perhaps modifying the timing of antigenic challenges to ensure persistent GCs 
is a more effective strategy at generating bnAbs.   
The data from this study further expand the etiological role of MBCs to not only 
recognizing pathogen escape variants but also heterologous antigens.  Our data suggest that the 
diversity of MBCs results from the continued active selection of lower affinity GC B cells into 
the MBC compartment.  Furthermore, the diversity of MBCs generated after a primary challenge 
is broad enough that further molding of the BCR towards new specificities via GC reactions is 
unnecessary after a secondary heterologous exposure.  Remaining questions include identifying 
the cues that are necessary to promote the preferential differentiation of broadly reactive GC B 
cells into the MBC compartment as well as determining if GC-biased MBCs can be activated 
upon recall in the presence of antigen-specific antibodies.  A better understanding of these 
processes has different implications for vaccine development for multiple pathogens, such as 
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